. As summarized in FIG. 1 , several endogenous mechanisms are involved in neurotoxic protein clearance. The glymphatic system and the blood-brain barrier (BBB) extrude neurotoxic proteins from the extracellular space, interstitial fluid (ISF) and cerebrospinal fluid (CSF), where they may also be degraded by proteases or phagocytosed by microglia and astrocytes. Within neurons and other cell types, intracellular elimination of neurotoxic proteins is predominantly effected by the ubiquitin-proteasome system (UPS) or by autophagy, a process by which superfluous or potentially dangerous cytoplasmic material is delivered to lysosomes for degradation. Three basic types of autophagy are recognized 3, 4 (FIG. 2) : microautophagy, in which cytosolic material is directly engulfed by invaginations of lysosomes; chaperone-mediated autophagy (CMA), which involves translocation of non-membrane bound, chaperonecaptured substrates across the lysosomal membrane; and macro autophagy, which involves sequestration of cytosolic material into de novo-synthesized, doublemembrane-bound autophagosomes that deliver their contents to lysosomes for digestion. The whole process, from the formation of the autophagosome isolation membrane to cargo digestion in the lysosome, is referred to as autophagic flux (BOX 1) . Macroautophagy is far better characterized than the other two types, so we use the term autophagy to refer to macroautophagy from this point on unless otherwise specified. 9, 10 , Michael R. Duchen 11 , Giovanna R. Mallucci 12 , Guido Kroemer [13] [14] [15] [16] [17] [18] [19] , Beth Levine 20, 21 , Eeva-Liisa Eskelinen 22 , Fanny Mochel 23 , Michael Spedding 24 , Caroline Louis 25 , Olivier R. Martin 26 and Mark J. Millan 25, 27 In this article, we first summarize the key aspects of the autophagic-lysosomal network (ALN), CMA and the UPS, and outline the nature of their disruption in NDAs. We then consider opportunities and challenges for intervening via these systems with the goal of clearing neurotoxic proteins in NDAs. Owing to its predilection for aggregated forms of neurotoxic proteins, as well as damaged organelles that also build up in NDAs, the ALN is an especially attractive target for disease modification and consequently a major focus of this article. However, it is unlikely that modulation of the ALN will prove to be a panacea 1, 4, 5 , and opportunities for harnessing non-ALN-driven mechanisms of clearance for course alteration of NDAs are discussed as well 2, 3 . We also review mechanisms for the clearance of extracellular neurotoxic proteins and strategies for their therapeutic enhancement. Finally, we analyse overarching issues for the characterization and development of therapies to promote neurotoxic protein clearance in NDAs.
The autophagic-lysosomal network Crucial role in clearing aggregated proteins. Autophagy is a phylogenetically conserved mechanism crucial for the intracellular clearance of burdensome proteins in all cell types, including neurons. Furthermore, astrocytes and several subtypes of microglia play important roles in the phagocytosis and subsequent autophagic elimination of extracellular pools of neurotoxic proteins [6] [7] [8] . In addition to bulk clearance of cytoplasmic contents, dedicated autophagy receptors promote sequestration of specific misfolded and/or aggregated proteins, damaged organelles, aggresomes, stress granules, peroxisomes, endo plasmic reticulum (ER) and Golgi apparatus components, lipids, ribosomes, polysaccharides and nucleic acids 4, 9 . The light chain 3 (LC3-II) and adaptor/scaffold receptor proteins such as optineurin and ubiquitinbinding protein p62 (also known as Sequestome 1 or SQSTM1) recruit discrete classes of protein to autophagosomes 10 . Other scaffolds include NIP3-like protein X (NIP3L; also known as BNIP3L), BCL-2/adenovirus E1B 19 kDa protein-interacting protein 1 (BNIP1) and prohibitin 2 in dysfunctional mitochondria 4, [9] [10] [11] 
Ubiquitin-dependent and non-ubiquitin-dependent autophagy occurs, with ubiquitylation of tau and other neurotoxic proteins enhancing capture by autophagic receptors such as p62. Post-translational modifications such as acetylation (for example, of Htt) may favour ALN degradation, but this possibility awaits further evaluation 12 . Autophagy can be constitutive or inducible, rapidly adapting to alterations in the internal and external environment of cells. Flexibility is important for maintaining normal brain function and for ensuring a constant supply of recycled amino acids, sugars, lipids and other products of ALN-mediated catabolism 3, 13 . The fact that autophagy serves an essential housekeeping role is demonstrated by genetic ablation of autophagy-related genes (ATGs). For example, mice with neuronspecific Atg7 or Atg5 deletions develop early postnatal neuro degeneration 14 , while knockdown of beclin 1 (the mammalian orthologue of yeast Atg6) exacerbates the vulnerability of hippocampal neurons to energy deprivation 15 . Moreover, postmitotic neurons cannot dilute harmful proteins via mitosis, so they are uniquely vulnerable to impairment of clearance 1, 3, 5, [16] [17] [18] . Maintaining efficient ALN flux (BOX 1) requires coordination of a suite of modulatory proteins and phospholipids 3, 10 (FIG. 3) . Changes in their amount, stoichiometry and function are characteristic of NDAs [1] [2] [3] 5, 10, [18] [19] [20] .
Sensing, initiation and regulation of ALN induction.
The heterotrimeric serine/threonine kinase 5ʹ-AMPactivated protein kinase (AMPK) and mammalian target of rapamycin complex 1 (mTORC1) trigger autophagy and repress mitophagy 3, 10, [20] [21] [22] [23] FIG. 3 ). Unc-51-like kinase 1 (ULK1) is primarily an autophagy-initiating protein 3, 10, 19 , as is the mTORC1-suppressed transcription factor EB (TFEB), which orchestrates the synthesis of lysosomal and other proteins critical for maintaining ALN flux [20] [21] [22] [23] . Because the class III deacetylase NADdependent protein deacetylase sirtuin 1 (SIRT1) requires Neurotoxic proteins (NTPs) are eliminated by a broad suite of specific and nonspecific mechanisms in neurons, glial cells and endothelial and/or vascular smooth muscle cells of vessels. The three major modes of intracellular clearance -the autophagic-lysosomal network (ALN), chaperone-mediated autophagy (CMA) and the ubiquitin-proteasome system (UPS) -are shown for neurons, but they are also active in other cells such as microglia. Under conditions of inflammation, proteasomal β-subunits in glia are switched and substrate specificity changes; the precise role of these 'immunoproteasomes' -which are specialized in peptide production for antigen presentation -for neurotoxic protein elimination in neurodegenerative diseases of ageing is debated 8 . Clearance also occurs in the extracellular space, the interstitial fluid (ISF) of the brain parenchyma, which surrounds neurons, and the cerebrospinal fluid (CSF) with which the ISF exchanges. Intraneuronal mechanisms of clearance are illustrated for NTPs in general, but only amyloid-β fragment 42 (Aβ42) is shown for extracellular clearance, as most currently available data are for this NTP. Extracellular pools of NTPs are derived from passive diffusion, active release from terminals, extrusion by exocytosis and dispersion upon cell death. NTPs disrupt neuronal and synaptic function and are taken up by other neurons and glial cells (spreading). Therapeutically relevant proteases degrading NTPs include endothelin-converting enzyme and insulin-degrading enzyme (IDE) (mainly cytosolic), neprilysin and matrix metalloproteinases (MMPs) (intracellular and extracellular) and plasmin (mainly extracellular). NTPs that escape glial capture and proteases are driven into the circulation. First, blood-brain barrier (BBB)-localized receptors and transporters, including P glycoprotein 1 transporter (also known as ATP-binding cassette subfamily B member 1, ABCB1) and low-density lipoprotein receptor-related protein 1 (LRP1), actively eject NTPs into the blood. Conversely, receptor for advanced glycation end-products (RAGE) returns Aβ to the central nervous system. Similar mechanisms operate at the blood-CSF barrier in the choroid plexus, for example, low-density lipoprotein receptor-related protein 2 (LRP2; also known as Megalin) transfer of transthyretin-bound Aβ from CSF into blood. Second, transfer of NTPs to the periphery is mediated through the glymphatic system. CSF runs along the peri-arterial space and transverses aquaporin 4 receptor-bearing circumvascular astrocytes to enter the ISF. Convective flow driven by arterial pulsing flushes NTPs via glial cells and the peri-venous space back into the CSF. Glymphatic-cleared, CSF-derived NTPs reach the circulation mainly via the cervical lymph nodes but also via the dural venous sinus. Within the blood, specific proteins sequester Aβ, such as the soluble fragment of LRP1 and immunoglobulins (IgG) . NTPs are ultimately eliminated in the kidneys and liver. APOE, apolipoprotein E; PICALM, phosphatidylinositol-binding clathrin assembly protein; sLRP1, soluble LRP1; sRAGE, soluble RAGE. Within neurons and other classes of cell, the ubiquitin-proteasome system (UPS) and chaperone-mediated autophagy (CMA) clear non-aggregated forms of neurotoxic protein, and the UPS also deals with substrates of endoplasmic reticulum-associated degradation (ERAD) of incorrectly folded proteins. Proteins destined for the proteasome are polyubiquitylated and guided to the proteasome by chaperones. They are deubiquitylated by 26S proteasome regulatory subunit RPN11 once committed to entering the proteasome pore; other deubiquitinases such as ubiquitin carboxyl-terminal hydrolase 14 (USP14) may rescue them before entry 49 . Unfolding is followed by degradation. CMA operates on proteins bearing a KFERQ-like motif. This sequence is found in, for example, tau but not amyloid-β (Aβ). Heat shock cognate 71 kDa protein (HSC70) recognizes the KFERQ sequence and, together with co-chaperones, transports the protein to the lysosome-associated membrane glycoprotein 2 (LAMP2A) receptor on lysosomes; LAMP2A then coordinates protein translocation into the lumen. The autophagic-lysosomal network is the major system for removing misfolded, higher-order, aggregated proteins as well as damaged organelles. Autophagosomes bearing cargo fuse with acidic lysosomes, leading to degradation of contents. In addition, some autophagosomes fuse with late endosomes. The resultant amphisomes then likewise fuse with lysosomes. See also FIG. 3 . E1, E1 ubiquitin-protein ligase; HSP70, heat shock 70 kDa protein; LC3-II, light chain 3; p62, ubiquitin-binding protein p62; Ub, ubiquitin. *Bulk or selective (such as ubiquitylated tau bound to ubiquitin-binding protein p62). 
Glymphatic system
A system that serves as a cerebrospinal fluid-driven mechanism for flushing extracellular pools of neurotoxic protein into the circulation; it involves perivascular drainage, astrocytes and the lymph system.
Blood-brain barrier
A physical and functional barrier that isolates the brain from the rest of the body. Certain nutrients, lipid vesicles and small molecules can enter, yet it excludes toxic elements that may damage the brain. It also ejects neurotoxic proteins and other unwanted material. Active transfer of neurotoxic proteins from the brain to the periphery involves specific classes of receptor and transporter.
Lysosomes
Acidic compartments for the degradation of proteins and other cellular constituents. Substrate breakdown yields products such as amino acids, sugars and lipids, which are recycled.
pathways that likewise modulate AMPK and mTORC1 (REFS [27] [28] [29] ). GPCR-mediated generation of cAMP can negatively regulate autophagy via, for example, protein kinase A (PKA)-mediated phosphorylation of ATG proteins 27, 29, 30 . Third, specific classes of cytokines and cytokine receptors also modulate autophagy, although events in the brain remain poorly defined 23 . AMPK is central to several mechanisms that trigger autophagy -most importantly, activating phosphorylation of ULK1 (Ser317 and Ser777) and inhibitory phosphorylation of mTORC1 (REFS 21, 31 ). Conversely, mTORC1 inhibits ULK1 by Ser757 phosphorylation 3, 4, 31 . mTORC1 also restrains autophagy by preventing nuclear translocation of TFEB 20 . Other transcription factors that positively regulate autophagy include forkhead box protein O1 (FOXO1) and FOXO3 (REF.
22
). Conversely, repression is effected by signal transducer and activator of transcription 3 (STAT3) and possibly zinc-finger protein with KRAB and SCAN domains 3 (ZKSCAN3), although its role has been disputed 22, 32 . SIRT1 is activated by AMPKmediated increases in nicotinamide, and it drives the ALN by inhibiting mTORC1, inducing FOXO1 and FOXO3 and activating key regulatory proteins such as ATG5, ATG7 and LC3. These actions are part of a broad palette of SIRT1-mediated neuroprotective effects in NDAs 24 .
Autophagosome formation, cargo sequestration and delivery to lysosomes. Activation of ULK1 triggers autophagosome nucleation through activating phosphorylation of AMBRA and beclin 1 within the autophagyspecific PIK3C3 complex 10 (FIG. 3) . LC3 and other family members such as GABA receptor-associated protein (GABARAP) covalently conjugate with phosphatidylethanolamine and assist in elongation of the isolation membrane and closure of autophagosomes 1, 3, 10, 33 . They also serve as docking sites for autophagy receptors that selectively capture ALN substrates 3 
Compared with glia, the complex structure of neurons complicates ALN degradation of neurotoxic proteins 1, 8, 10, 18 . Autophagosomes formed in synaptic terminals and neurites must be retrogradely transported with the aid of microtubules and dynein-dynactin Characterization of the autophagic-lysosomal network (ALN) and its therapeutic restitution in neurodegenerative disorders of ageing (NDAs) necessitates accurate interpretation of autophagic states both in vitro and in vivo 10, 23 . While electron microscopy has traditionally been used to observe key features of autophagosomes, recently introduced approaches allow for more refined analysis of the ALN, for example, whether increases in autophagosome number (the most common measure undertaken) reflect an increase in their synthesis or, rather, decreased ALN flux 23 . Because membrane-bound light chain 3 (LC3-II; the mammalian homologue of Atg8) is covalently conjugated to phosphatidylethanolamine on the outer and inner autophagosomal membranes (FIG. 3) , its expression and localization are widely used to track autophagic kinetics. Calculating the ratio of LC3-II to tubulin is a popular method for measuring cellular autophagosome levels by immunoblot 17 . Green fluorescent protein (GFP)-tagged LC3 has proved especially useful for quantifying autophagosomes, but self-aggregation of cytosolic GFP-LC3 and the quenching of GFP fluorescence in acidic lysosomes complicates interpretation in cytological assays 23 . To overcome GFP quenching, tandem constructs containing GFP and an acid-resistant red fluorescent protein (DsRed or mCherry) can be used to discriminate autophagosomes (and amphisomes) from autolysosomes (FIG. 3) . To show that increased levels of LC3-II genuinely represent accelerated ALN flux, it is useful to use compounds such as bafilomycin A or chloroquine, which neutralize lysosomal pH and produce an additive elevation in LC3-II levels under conditions where ALN flux is indeed high. Levels of ubiquitin-binding protein p62 or other cargo acceptors are also useful readouts: a decrease in p62 often accompanies accelerated autophagic flux, while its accumulation may indicate a decrease. Potential variables that complicate p62 measurement include its proteasomal degradation, alterations in transcription and reduced global protein synthesis in degenerating cells 315 . Therefore, parallel monitoring of SQSTM1 (which encodes p62) mRNA levels and ubiquitinproteasome system status is recommended 229 . Phospho-specific antibodies that detect activation states of key autophagy regulatory kinases such as 5ʹ-AMP-activated protein kinase (AMPK), mammalian target of rapamycin complex 1 (mTORC1) and Unc51-like kinase 1 (ULK1) are also instructive indicators of ALN status.
In regard to in vivo models, zebrafish (Danio rerio) larvae are transparent and permit visualization of ALN reporters such as GFP-LC3-II constructs and neurotoxic proteins 316 . Furthermore, targeted gene transduction, deletion or editing can easily be performed by morpholinos and the CRISPR-Cas9 system. Comparatively high-throughput screening can also be undertaken with compounds added to water that are absorbed transdermally 103 . For example, stimulating autophagy and transcription factor EB (TFEB) nuclear translocation by trifluoperazine prevented neuronal loss in PTEN-induced putative kinase 1 (PINK1)-deficient zebrafish 317 . Fruitflies (Drosophila melanogaster) are also useful. They can be rendered autophagy deficient, resulting in spontaneous neurodegeneration, while restoration of autophagy is neuroprotective in Pink1 mutants 318 . In addition, genetic tools are available for manipulating each step of ALN disruption, while somatic, mutant clones in subsets of specific neurons permit evaluation of ALN status in impacted cells surrounded by wild-type tissue 319 . D. melanogaster models have also been used to validate the effects of drugs regulating the ALN: for example, rapamycin had beneficial effects in a polyglutamine model of HD 133 . Nonetheless, mice remain the most common in vivo preclinical model for modulation of the ALN in NDAs 23 , and a broad range of pharmacological agents have been studied, as summarized in TABLE 2. Apart from the brain, retinal tissue has also proved instructive, for example, in evaluating axonal transport of acidic vesicles to lysosomes 312, 320 . Finally, for in vitro and in vivo studies of the ALN, overexpression of mutant proteins associated with NDAs is often used as a model of proteinopathy burden. However, this may not faithfully recapitulate sporadic forms of disease, and the importance of other factors influencing the ALN, such as endoplasmic reticulum stress, the cytosolic and mitophagic unfolded protein response (Supplementary Box 3) and diminished energy supply, should be borne in mind 25, 57, 58, 99, 321 .
Aggresomes
Microtubule-associated inclusions located in the perinuclear region that contain mainly oligomeric, aggregated and ubiquitylated neurotoxic proteins together with ubiquitin-binding protein p62 and chaperones that aid in their formation. Aggresomes are often generated when ubiquitin-proteasome system activity is insufficient. Although they are protective when short-lived, they may be harmful in the long term and can morph into Lewy bodies in Parkinson disease. Aggresomes are cleared by the autophagiclysosomal network.
Stress granules
Non-membrane enclosed, cytoplasmic agglomerates of ribonucleoproteins that store and protect mRNA during short-term cellular stress. Chaperones such as heat shock 70 kDa protein (HSP70) are involved in assembly and unfolding. In neurodegenerative diseases of ageing, neurotoxic proteins prolong the presence of stress granules and decrease their solubility, leading to aggregation or transformation into aggresomes.
Peroxisomes
Small (100 nm to 1 μm) organelles that oxidize long-chain fatty acids and aid in detoxification. They can be generated by budding-off from the endoplasmic reticulum and replicate via fission. Pexophagy refers to the autophagy of peroxisomes.
Autophagy-related genes (ATGs). Genes and the molecular machinery for autophagy were characterized in yeast by Y. Ohsumi and others. The associated genes, identified using mutants, were originally termed Apg1-Apg15, yet ATG is now used. In view of conservation across species, this terminology is used for genes and/or proteins that regulate autophagy in humans as well.
motor complexes to the perikarya, where lysosomal fusion occurs 10, 16, 34 . Many autophagosomes fuse with late endolysosomal compartments containing membrane-localized RAS-related protein RAB7 (a GTPase) and lysosome-associated membrane glycoprotein 1 (LAMP1) before reaching the perikaryon. This implies that the ALN process is partly initiated in advance of fusion with mature lysosomes and full luminal acidification, a process completed upon arrival in the perikaryon 10, 16, 34, 35 (FIG. 2) .
Autolysosome formation is facilitated by the retromer complex, which is itself retrogradely transported to cell bodies 36, 37 . SNARE proteins and the homotypic fusion and vacuole-protein sorting (HOPS) complex bridge mature autophagosomes and/or amphisomes to lysosomes to initiate fusion 4, 19 . RAB proteins, LAMP1 and LAMP2 collectively aid in autophagosome maturation and lysosomal fusion, which is also dependent on membrane constituents such as phospholipase D1 (PLD1), phosphoinositols, other phospholipids and cholesterol 10, 19, 38 .
Lysosomal digestion of cargo. Autophagosomes fuse with lysosomes, which provide the hydrolases required for cargo degradation 3, 4, 9, 39 . Hydrolases are dependent on a low pH, and lysosomal acidification is promoted
Box 2 | Defective mitophagy and its restoration for treatment of neurodegenerative disorders of ageing
Mitochondria support the high energetic costs of a complex and dynamic neuronal architecture, synaptic transmission and, last but not least, operation of the autophagic-lysosomal network (ALN). Indeed, mitochondrial function and the ALN are reciprocally interlinked. For example, generation of reactive oxygen species and ATP depletion induce the ALN via 5ʹ-AMP-activated protein kinase (AMPK), which will, in turn, eliminate damaged mitochondria 21, 322 . In fact, there are several quality control mechanisms that preserve healthy mitochondrial populations: fusion and fission cycles to redistribute mitochondrial content and isolate damaged mitochondria; chaperones for ensuring maturation and folding of mitochondrial proteins; proteases for degrading misfolded mitochondrial constituents; lysosome-dependent pathways for destruction of damaged mitochondria; and a specific mode of the unfolded protein response that preserves mitochondrial proteostasis 57, 255, 323 . Mitophagy refers to a type of macroautophagy that leads to degradation of mitochondria 9, 70, 323 (FIG. 2) . While crucial for many developmental programmes, mitophagy has a more generalized, protective role in preventing the accumulation of reactive oxygen species and the release of pro-apoptotic factors. Of particular relevance to neurodegenerative disorders of ageing (NDAs) is a stress-responsive, mitochondrial degradation cascade co-regulated by two genes known to be mutated in familial Parkinson disease (PD): the mitochondrial kinase PTEN-induced putative kinase protein 1 (PINK1) and the E3 ubiquitin-protein ligase, parkin 69, 70 . This cascade, driven by PINK1-dependent activation of parkin and ubiquitylation of proteins in dysfunctional mitochondria, is a well-characterized pathway of mitochondrial clearance, and studies using fluorescent reporter systems to track mitochondria in autophagosomes and lysosomes have highlighted its important role in neurons 324 . PINK1 may also clear damaged mitochondria independently of parkin by recruiting autophagy receptors like optineurin, for example, in Alzheimer disease (AD), where PINK1 appears to be deficient 325 .
Whether driven by the PINK1-parkin system or other ubiquitin-dependent or ubiquitin-independent mechanisms, mitophagy decreases with age. Furthermore, while mitophagy may be compensatorily augmented at the onset of NDAs, in later phases, it is generally disrupted 9, 75, 323 . There is a complex interplay between protein aggregation, mitochondrial dysfunction and mitophagy. Aggregation-prone proteins, such as amyloid-β (Aβ), superoxide dismutase 1 (SOD1) variants and α-synuclein, are imported into mitochondria 326 . This may reflect an adaptive mechanism that uses mitochondria to clear aggregates 255 . However, in the long run, aggregation-prone proteins such as α-synuclein provoke mitochondrial dysfunction and block mitochondrial protein import. Stimulating mitophagy may thus improve both mitochondrial function and cytosolic proteostasis 58, 255, 326 . As for pharmacological approaches for promoting mitophagy in NDAs 327 , some are the same as those inducing cytosolic autophagy. More specifically, several strategies aim to activate PINK1-parkin-driven mitophagy, for example, by the neo-substrate, kinetin triphosphate, which enhances PINK1 kinase activity 328 . Small-molecule transcriptional activators of parkin have also been proposed 329 . Other approaches use iron chelators to induce PINK1-parkin-independent mitophagy. The ubiquitin-specific deubiquitinase, ubiquitin carboxyl-terminal hydrolase 30 (USP30), negatively regulates the initiation of parkin-mediated removal of damaged mitochondria; its structurally distinct features in comparison with other deubiquitinases are encouraging interest in its use as a parkin-related drug target 227, 330 . Two other deubiquitinases, USP8 (which delays parkin binding to damaged mitochondria) and USP15 (which suppresses parkin-driven mitophagy) are also under scrutiny as targets for promoting mitophagy in NDAs 217 . The inner mitochondrial membrane protein prohibitin 2 directly binds light chain 3 (LC3-II) to target ruptured mitochondria for degradation; it is depleted in human PD brain 11 . Because prohibitin 2 overexpression is protective in cellular models of PD, it is an interesting target for potential therapy 331 . Compounds that stabilize nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2) are also of interest because NFE2L2 triggers parkin-independent mitophagy by a mechanism involving activation of ubiquitin-binding protein p62 332 . Replenishment of nicotinamide, which declines with age 56 , may promote mitochondrial clearance by activating NAD-dependent protein deacetylase sirtuin 1 (SIRT1)-driven mitophagy 333 . Furthermore, in promoting mitochondrial proteostasis, nicotinamide derivatives opposed the deposition of Aβ in cellular and mouse models of AD 58 . The plant flavanol kaempferol induces autophagy and exerts protective effects on mitochondria, for example, against toxins triggering PD-like dysfunction. Its actions involve induction of RAC serine/threonine-protein kinase (AKT) upstream of mammalian target of rapamycin complex 1 (mTORC1) 334 . Other natural compounds, such as urolithin A, promote mitophagy by mechanisms that remain to be determined 335 . Finally, lifestyle factors, such as exercise and intermittent fasting, favour mitochondrial and neuronal health by a combination of mechanisms that include the stimulation of mitophagy 9, 25, 164, 207 .
5ʹ-AMP-activated protein kinase
(AMPK). An enzyme involved in energy and nutrient sensing. When activated, AMPK triggers glucose uptake, lipogenesis and triglyceride synthesis. It is a major protein for sensing ATP deficits and initiating the autophagic-lysosomal network.
by the vacuolar-type H + -ATPase complex (v-ATPase), which pumps protons into the lysosomal lumen. The electrogenic potential created by proton import is mediated by multiple ion channels that influence lysosomal pH 40 . Underpinning the importance of acidity, digestion can be halted by v-ATPase inhibitors such as bafilomycin A 41 and lysosomotropic basic amphiphiles such as chloroquine that alkalinize the lysosomal lumen 42 . Furthermore, a deficiency of lysosomal cathepsins (cathepsin B, cathepsin L, cathepsin D, etc.) prevents protein degradation and leads to accumulation of undigested cargo 16, 17, 39 . Lysosomal dysfunction blocks flux across the entire ALN, as evidenced by lysosomal storage disorders (LSDs) such as Niemann-Pick type C disease that manifest with neuropathological phenotypes 43 (Supplementary Box 1). In addition to ALN function, the importance of maintaining lysosomal activity reflects a broader role in, for example, regulation of cytosolic Ca 2+ and energy homeostasis 44 .
Chaperone-mediated autophagy Like macroautophagy, CMA is important for amino acid recycling during periods of poor nutrient availability, but by contrast, it involves transfer of protein substrates for , while the bottom part shows the main regulatory proteins involved, focusing on potential targets for pharmacotherapy. Sensing -both extrinsic (for example, glucose levels) and intrinsic (for example, ATP/AMP levels) -can determine whether or not autophagy is initiated by activation of 5ʹ-AMP-activated protein kinase (AMPK) and/or inhibition of mammalian target of rapamycin complex 1 (mTORC1), which leads to transcription factor EB (TFEB)-driven transcription of ALN-requisite proteins. The pre-autophagosome (phagophore) structure first emerges from diverse membrane sources, and its formation is promoted by autophagy-related gene 9 (ATG9) (not shown). Nucleation is accomplished with the help of the PIK3C3 cluster of proteins. Phosphatidylinositol-3-phosphate (PtdIns3P), generated by Vps34, is recognized by WD repeat domain phosphoinositide-interacting (WIPI) proteins that help to induce autophagosome elongation in association with several classes of ATG protein and small GTPases such as RAS-related protein RAB5. With the aid of LC3 and cargo acceptors, autophagosomes take up cytoplasmic material such as aggregated proteins and dysfunctional mitochondria degradation into the lysosomal lumen without enclosure by any membrane structure [45] [46] [47] (FIG. 2) . With the help of heat shock protein HSP90 (HSP90) and other cochaperones, heat shock cognate 71 kDa protein (HSC70; also known as HSPA8) recognizes soluble, cytosolic proteins bearing a KFERQ motif or an equivalent motif and guides them to the transmembrane LAMP2A receptor [1] [2] [3] [4] [5] 10, 47 . The substrate complex binds to the cytosolic tail of LAMP2A, leading to LAMP2A stabilization and oligomerization. Following unfolding, the protein cargo is then translocated into the lysosomal lumen. This process is aided by a specific, low pH-dependent lysosomal form of HSC70 (lysine-HSC70), which promotes dissociation of the LAMP2A multimer so that the monomeric form is again available for substrate recognition and import. The level of LAMP2A determines the rate of CMA.
In contrast to the ALN, CMA is not devoted to the degradation of higher-order neurotoxic proteins and aggregates, but it is important for clearing oxidized proteins. Tau, α-synuclein and TDP43 are substrates for CMA degradation, as are amyloid precursor protein (APP) but not amyloid-β fragment 42 (Aβ42) itself 3, [45] [46] [47] 48 . Htt is not efficiently cleared by CMA, and the same appears to hold for its fragments and mutant and posttranslationally modified forms, although the precise role of CMA in Htt elimination remains to be more fully defined 2, [45] [46] [47] .
The ubiquitin-proteasome system The UPS mainly targets soluble and monomeric proteins rather than aggregates using a process involving heat shock 70 kDa protein (HSP70) and the sequential actions of three classes of ubiquitin ligase (E1, E2 and E3). These ligases effect the addition of ubiquitin residues onto targeted proteins, often as polyubiquitin chains, at single or multiple lysine sites 2, 3, 8, 48, 49 (FIG. 2) . Ubiquitylated substrates are recognized by the 19S regulatory particle of the UPS. After binding to the RPN subunits of the 19S ring, ubiquitin motifs are removed by three enzymes, ubiquitin carboxyl-terminal hydrolase 14 (USP14), ubiquitin C-terminal hydrolase UCH37 (also known as UCHL5) and the 26S proteasome regulatory subunit RPN11 (also known as PSMD14). RPN11 removes ubiquitylation chains only after substrates are committed to destruction, whereas USP14 and probably UCH37 act before commitment and hence can rescue substrates 49 . Following removal of ubiquitin moieties, proteins are unfolded by the 26S proteasome AAA-ATPase subunit RPT1 (also known as PSMC2), RPT2 (also known as PSMC1), RPT3 (also known as PSMC4), RPT4 (also known as PSMC6), RPT5 (also known as PSMC3) and RPT6 (also known as PSMC5) subunits (ATPases) of the 19S component. The substrate then passes the α-subunit gate of the 20S core particle to enter its central β-subunit, which possesses peptidase activity (trypsin, chymotrypsin and caspase-like activity) and effects proteolysis.
In addition to ubiquitylated substrates, the UPS can also handle oxidized proteins, which may accumulate under conditions of cellular stress 8, 50 . Furthermore, as well as cytosolic proteins, the UPS degrades mitochondrial proteins that build up upon failure of mitochondrial import or sorting 51 . It also operates in the nucleus. Interestingly, the UPS is important for elimination of tau and other neurotoxic proteins in post synaptic dendritic compartments (a key site of spreading), where it plays a more general role favouring synaptic plasticity, dendritogenesis and memory formation 49, 52 . Susceptibility of neurotoxic proteins to ubiquitylation is modified by phosphorylation and other post-translational modifications 3, 8, 49, 51 .
Impaired intracellular protein clearance
Neurons adopt multiple strategies to deal with potentially dangerous proteins. With the aid of chaperones such as HSP70, anomalously configured proteins may be refolded or, if clumped in aggregates, disassociated 2, 3, 53 . Neurotoxic proteins may also be sequestered in insoluble tangles (for example, as with tau) or in microtubuleassociated aggresomes 2, 4 . This intracellular lock-up may, at least initially, be neuroprotective, but continuing accumulation eventually poses a threat to cells, underscoring the importance of elimination 2, 4 . While clearance systems are, at least initially, recruited in NDAs, they eventually become unable to cope with the additional neurotoxic burden 1, 5, 9, 18, 54, 55 (TABLE 1) . The partly common and partly disease-specific patterns of ALN, CMA and UPS disruption in NDAs are superimposed upon a generalized, age-related decline in clearance in both neurons and other cell types such as microglia 1, 2, 7, 18, 46, 47, 55, 56 .
Insufficient neuronal ALN flux is frequently manifested by lysosomal accumulation of lipofuscin

18
. For optimization of therapy in NDAs, accurate interpretation of the causes of impaired elimination of neurotoxic proteins is paramount. This is challenging because impaired elimination may be a repercussion of upstream anomalies such as protein overproduction, protein misfolding or an excessive cytosolic unfolded protein response (UPR) 57 (Supplementary Box 2). Furthermore, it is difficult to identify the exact nature of UPS, CMA and ALN dysfunction (BOX 1). While inadequate ALN flux is a common problem for most if not all NDAs, under certain conditions, ALN overactivity may contribute to pathology and even autosis 4 
in ALS (Supplementary Box 3).
The following paragraphs and TABLE 1 summarize the complex patterns of defective neurotoxic protein clearance seen in specific classes of NDAs.
Alzheimer disease. Although induced in the early-phase of AD 1, 3, 47, 58 , ALN-mediated, UPS-mediated and CMAmediated clearance eventually becomes overwhelmed and impaired. First, autophagosomes and autophagic vacuoles indicative of failed maturation, transport and/ or fusion with lysosomes are abundant, particularly in dystrophic neurites. Their accumulation may be linked to impaired lysosomal elimination of cargo 18 . Second, while decreases in beclin 1 levels in AD remain to be confirmed, SIRT1 expression is diminished 24 . Third, apolipoprotein E allele 4 (APOE4), a major risk allele for sporadic AD, is associated with increased generation and accumulation of Aβ42 (REFS 59, 60 ). APOE4 slows lysosomal Aβ42 clearance and, like Aβ42 itself, destabilizes lysosomal 
KFERQ
The KFERQ motif on a protein is the principal criterion for capture followed by chaperone-mediated autophagy (CMA). Q refers to glutamine, although this sometimes may be an asparagine (N). The other residues are acidic (D and E), basic (K and R) or basic and/or hydrophobic (F). There are, however, variations, and post-translational modification can modify susceptibility of proteins bearing a KFERQ signal for CMA.
membranes. In addition to decreased degradation, one consequence is leakage of asparaginyl endopeptidase into the cytosol, where it generates toxic fragments of tau 61 . Moreover, APOE4 impairs the elimination of Aβ42 and tau by astrocytes and microglia, which are additionally compromised by decreased activity of triggering receptor expressed on myeloid cells 2 (TREM2) 7, 62 . Fourth, genetic mutations and anomalies of presenilin 1, a dominant negative gene linked to AD, are associated with reduced lysosomal v-ATPase-mediated acidification 40, 63 , a compromised ALN and deficient mitophagy 64 . Presenilin 2, likewise an autosomal dominant risk gene, is enriched in late endosomes and/or lysosomes, where its dysfunction provokes lysosomal accumulation of insoluble Aβ42 and possibly tau 65 . Fifth, mutations in APP similarly disrupt endosomal and lysosomal function, in part owing to accumulation of the β-secretasegenerated, carboxy-terminal and Aβ42-containing fragment of APP called C99 (REF.
66
). Sixth, Aβ42 compromises the function of AMPK to impede initiation of the ALN 67 . Seventh, Aβ42 obstructs the UPS and CMA 47, 68 . Both aggregates and mutant forms of tau likewise block the proteasome, and its ability to degrade hyperphosphorylated and oligomeric tau is reduced compared with its ability to degrade physiological tau 3, 55, 68 . Finally, while physiological tau possesses KFERQ motifs and is degraded by CMA, aggregates, mutant forms and fragments interfere with CMA 45, 47 .
Parkinson disease. Disrupted proteostasis is also a major feature of PD, with the efficiency of the ALN, CMA, the UPS and other modes of clearance compromised by multiple cellular anomalies. First, autosomal recessive forms of early-onset PD are associated with mutations in PTEN-induced putative kinase protein 1 (PINK1) and the E3 ubiquitin-protein ligase parkin; these mutations lead to deficits in the mitophagic removal of damaged mitochondria 69, 70 
. Second, the GTPase leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) is the most commonly mutated protein in late-onset, familial PD. Its role is complex, with both loss and gain of function mutations. Some of these lead to an impairment of the ALN owing to reduced activation of beclin 1; another repercussion may be altered processing of APP, providing an unexpected link to AD 69, [71] [72] [73] . Third, α-synuclein mutations, triplications or excesses amplify the ALN burden, interfere with auto phagosome formation and irreversibly disrupt the lysosomal membrane 1, 3, 44, 56 . Fourth, homozygous mutations of lysosomal β-glucocerebrosidase (βGCase; also known as GBA) provoke the LSD Gaucher disease, which is linked to decreased ALN flux, α-synuclein accumulation and a fivefold increase in risk of PD 43 (Supplementary Box 1). Decreased βGCase activity also occurs in sporadic PD, leading to the build-up of glucosides, lipid dyshomeostasis, poor clearance of α-synuclein and impaired lysosomal activity 43, 74, 75 . Fifth, defects in several genes disrupt lysosomal acidification 40 . For example, disruption of cation-transporting ATPase 13A2 (ATP13A2), which is also depleted in sporadic PD, leads to lysosomal alkalization and digestive failure 76 in addition to accumulation of α-synuclein and other ubiquitylated proteins [76] [77] [78] . Sixth, aggregates and mutant forms of α-synuclein disrupt the proteasome in dopaminergic neurons. Furthermore, mutations in the gene encoding parkin and several other genes are linked to reduced UPS activity 2, 56, 69, 79, 80 . Finally, oligomeric and mutant forms of α-synuclein impair LAMP2A-mediated cargo transport for CMA, while levels of both LAMP2A and HSC70 are reduced in brains from PD patients 45, 47, 55, 80 . In addition, CMA is disrupted by several genetic mutations occurring in PD, including mutations in LRRK2 (REFS 2, 3, [45] [46] [47] 55, 69, 80 ). CMA dysfunction in PD favours the accumulation of α-synuclein and leads to inactivation of the dopaminergic neuron survival factor, myocyte-specific enhancer factor 2D (MEF2D) 2, 45, 47, 55 .
Frontotemporal dementia. As FTD was initially associated with tau mutations, it was originally considered a 'tauopathy' 81, 82 . However, in light of common risk genes such as SQSTM1 (which encodes p62) and chromosome 9 open reading frame 72 (C9ORF72), FTD is increasingly linked to ALS 82, 83 . Genetic anomalies in FTD are closely related to a deficient ALN, and like ALS, the disease is characterized by aggregates containing tau, TDP43, RNA-binding protein FUS and other ubiquitylated proteins insufficiently cleared by the ALN 82, 84 . Aggregates interfere with the UPS to create a vicious circle that further overloads the ALN 1, 18, 55, 56, 68, 84 . Recently, it was found that polyglycine or polyalanine tracts linked to mutant forms of C9ORF72 form twisted ribbon aggregates that sequester and stall the activity of proteasomes 85 . MAPT (which encodes tau) is a distinctive risk gene for FTD versus ALS, and dissociation of tau from microtubules disrupts retrograde transport of autophagosomes to the lysosome 81, 82 . In addition, lysosomal dysfunction and loss of acidification are caused by tau fragments and a deficit of progranulin 40, 82, 83, 86 , while an interrelated deficiency of endosomal trafficking is linked to mutations in CHMP2B (which encodes charged multivesicular body protein 2B) and C9ORF72 (REFS 82, 83 ).
Amyotrophic lateral sclerosis. ALS shares many causal genes with FTD, including SQSTM1, CHMP2B, TBK1
(which encodes tank-binding kinase 1), OPTN (which encodes optineurin) and other genes associated with deficits in ALN and mitophagy. For example, mutations in OPTN and TBK1 interfere with cargo loading 82, 84, 87 . Mutations in C9ORF72 (the most prevalent risk gene for familial ALS and FTD) are likewise linked to disruption of the ALN, including interference with dynactin-dynein coordinated transport of autophagosomes along axons of motor neurons to the perikarya 82, 88 . They also lead to deregulation of RAB GTPases and a failure of autophagosome elongation 89 . Paradoxically, however, certain anomalies of C9ORF72 may stimulate the ALN, and under conditions of severe cellular stress, high ALN activity may be detrimental 48, 88, 90 (Supplementary Box 3). In any event, depending on their genetic profiles, patients with ALS carry aggregates of risk gene-encoded proteins like TDP43, optineurin, FUS and/or superoxide dismutase 1 (SOD1) 48, 82, 84, 87, 89 . Aggregated SOD1 and TDP43 disrupt CMA and the UPS -with the latter also impaired by 
ALN dysfunction
Underactive autophagy is a term used when rates of autophagosome formation and cargo sequestration decrease below basal levels or fail to upregulate sufficiently under stress. Impaired autophagy occurs when lysosomal delivery, fusion or digestion of autophagosomes are compromised. Overactive autophagy is the overproduction of autophagosomes and excess autophagic-lysosomal network activity; this can lead to autosis.
Autosis
Autophagy-related cell death mediated principally by the Na + /K + -ATPase pump. This can occur with prolonged and excessive autophagy. It is triggered by hypoxiaischaemia (as in stroke or traumatic brain injury), but its occurrence in neurodegenerative disorders of ageing is uncertain. mutations in C9ORF72 (REFS 2, 8, 47, 48, 55, 85, 91 ). Thus, mirroring other classes of NDA, a failure to clear neurotoxic proteins is characteristic of ALS 48, 82, 84 .
Huntington disease. In this autosomal dominant, polyglutamine disorder, an increase in CAG expansion repeats in HTT magnifies the propensity of Htt to oligomerize 2, 3, 55, 80 . Mutant Htt is cleared by autophagy, but it compromises the ALN because of decreased cargo loading and impaired autophagosome formation and transport 55, 56, 68, 92 . Furthermore, ALN disruption in the striatum (a region strongly affected in HD) involves altered activity of the striatum-specific beclin 1 and Htt-interacting protein GTP-binding protein RHES 93, 94 . In addition, loss of physio logical Htt and the presence of abnormal poly glutamine-Htt perturb neuronal cilia -which are important sites of cellular communication and signalling that reciprocally interact with autophagic mechanisms controlling their formation and growth 92 . CMA handles mutant and post-translationally modified forms of Htt poorly, as they interfere with its activity 2, 45, 47, 95 . While LAMP2A and HSC70 are upregulated in early HD to compensate for decreased ALN clearance, CMA eventually fails in parallel with neuronal loss 47, 96 . The status of the UPS in HD is currently unclear, but it cleaves mutant forms of Htt (and other polyglutamine tracts) poorly, while animal models suggest that it is impaired in HD (which would further lead to reduced clearance of Htt) 97 .
Enhancing clearance by the ALN Ultimately, any strategy that improves protein quality control and reduces excessive generation, aberrant processing and/or abnormal folding of neurotoxic proteins should moderate the ALN burden and facilitate clearance. For example, agents that promote folding of nascent proteins, prevent misfolding, refold aberrantly configured proteins, dissociate aggregates, counter ER stress and/or blunt an excessive UPR might preempt the build-up of neurotoxic proteins 1, 2, 54, 56, 57, 84, [98] [99] [100] (Supplementary Box 2). However, this article focuses on strategies for elimination of neurotoxic proteins (FIG. 4;  TABLE 2 ). It should be noted that the precise mechanisms of drug action are not invariably well-defined 4 and that certain agents exert multiple beneficial (or deleterious) actions. For example, methylene blue counters tau oligomerization and promotes autophagy 101, 102 (Supplementary Table 4 ). In addition, several agents such as resveratrol interact at multiple nodes of the ALN. Indeed, future drugs designed to act in a multi-modal manner may prove to be the most effective for improving neurotoxic protein clearance in NDAs.
The following paragraphs mainly relate to classical small-molecule drugs; innovative treatment modalities for reinforcing clearance are outlined in BOX 3.
Direct and indirect activators of AMPK-induced autophagy. Ligands inhibiting GPCRs coupled to adenylyl cyclase (AC)-cAMP are potential activators of AMPK 27, 29 . Indeed, clonidine and rilmenidine, two G i /G o -coupled α 2 -adrenergic receptor and imidazoline 1 receptor agonists, stimulate autophagy and cleared Htt in cellular 103 and animal models of HD 104 . Although their mechanisms of action await further elucidation 21, 103, 104 and may be partially AMPK/mTOR independent, there may be a role for calpain 1 and calpain 2. These Ca 2+ -activated cysteine proteases are elevated in ageing and proteolytically generate various neurotoxic peptides 54, 81 . They stimulate AC-cAMP to inhibit autophagy by activation of the G S α-subunit 103 . Genetic knockdown of calpain 1 or calpain 2 or overexpression of their endogenous inhibitor, calpastatin, increased autophagy and cleared aggregates in SK-N-SH cells overexpressing a mutant form of Htt 103 . Efficacy was also seen in mutant Drosophila melanogaster and mouse models of HD 54 . Calpeptin, a cell-permeable calpain inhibitor, can also reduce Htt proteinopathy via induction of autophagy 103, 105 . Calpain inhibition by calpastatin or pharmacological agents also confers neuroprotective effects in other NDA models, including improved clearance of tau, α-synuclein and SOD1 (REFS 54, 106, 107 ).
The aminoimidazole derivative 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) undergoes intracellular transformation to an AMP analogue that triggers AMPK-mediated autophagy 21, 108 . It conferred neuroprotection upon exposure of astrocytes to Aβ or oxidative stress 109 and countered α-synuclein toxicity in cultured rat neurons 110 . Another direct facilitator of AMPK, A769662, elicited autophagy and reduced the burden of Htt in a striatal cell line derived from knock-in mice expressing a humanized form of mutant Htt (exon 1 containing seven polyglutamine repeats) 111 . Selenium deficits have been linked to AD, and thus it is interesting that selenomethionine boosted ALN flux, from AMPK recruitment through autophagosome formation to lysosomal degradation, in the 3×Tg AD mouse model 112 . The 'anti-ageing' agent resveratrol is thought to indirectly recruit AMPK via activation of calcium/calmodulindependent protein kinase kinase 2 (CAMKK2), which, acting in synergy with Ca 2+ , exerts its effects via Thr172 phosphorylation 113 . This action, among others (below), is involved in its reduction of Aβ levels in N2a cells and neurons 114 and the elimination of Aβ and Htt in animal models of AD and HD 114, 115 . The antidiabetic drug metformin, a prototypical activator of AMPK, induced autophagy and increased longevity in mice 116 . Like AICAR, metformin abrogated α-synuclein toxicity in primary cultures of cortical neurons, although the precise contribution of autophagy requires clarification 110 . Moreover, reductions in levels of hyper phosphorylated tau and Aβ were seen in metformintreated neurons 117, 118 , while it blunted neuronal loss in a neurochemical lesion model of PD in mice 119 . The di-glucose derivative trehalose inhibits the solute carrier 2A (SLC2A) family of glucose transporters to promote AMPK-induced autophagy and reduce neurotoxic protein load, although it also exerts other actions downstream in the ALN 4, 120 . Trehalose promoted autophagy and reduced disease progression in a SOD1 mouse model of ALS 120 . It also proved effective in cellular models of PD, HD and AD 121, 122 , as well as in mouse models of HD, AD and tauopathies, where it cleared aggregates, reduced neurodegeneration and ameliorated motor and cognitive performance [123] [124] [125] . Lithium ions inhibit inositol monophosphatase to deplete inositol triphosphate. This mechanism may be involved in its promotion of autophagy, reduction in cellular levels of α-synuclein, SOD1, Htt and tau 126 , amelioration of motor function in a P301L mouse model of tauopathy 127 and slowing of disease progression in SOD1 mice 128 . However, its precise mechanism of action awaits further elucidation 126 .
Other compounds that act through AMPK activation include the antiaggregant methylene blue (Supplementary Box 1) , which elevated levels of beclin 1, p62 and LC3, induced autophagy and suppressed tau in organotypic neuronal cultures and a mouse model of FTD 101, 102 . In addition, calcitriol (the active metabolite of vitamin D 3 ) elicited AMPK-dependent autophagy in a neurochemical lesion-induced model of PD 129 .
Modulators of mTORC1 and its transcriptional control of the ALN. One major strategy for promoting autophagy is the relief of its repression by mTORC1. This kinase is classically inactivated by rapamycin, which binds to the modulatory protein 12 kDa FK506-binding protein depicted, yet precise mechanisms of action remain to be more fully deciphered for many drugs, while several agents like resveratrol act at multiple sites (see the main text). As illustrated, a broad range of drugs exert their actions via 5ʹ-AMP-activated protein kinase (AMPK), mammalian target of rapamycin complex 1 (mTORC1) or NAD-dependent protein deacetylase sirtuin 1 (SIRT1) (which also influences downstream events such as autophagosome formation). Some agents exert their effects via other components of the ALN, up to and including lysosomal catabolism. In addition, ambroxol acts as a chaperone to help transport β-glucocerebrosidase (βGCase) to lysosomes. Diverse classes of agent likewise promote UPS activity, including chaperones that assist in protein refolding and triage, modulators of proteasomal phosphorylation and agents acting via the transcription factor nuclear factor Nrf2 (also known as erythroid 2-related factor 2, NFE2L2) to induce coordinated synthesis of proteasomal subunits. Extraneuronal clearance of full-length, truncated, post-translationally modified, monomeric and/or higher-order neurotoxic proteins can be promoted by stimulating proteases like neprilysin, immunotherapies targeting specific neurotoxic proteins and increasing BBB-mediated and glymphatic extrusion into the circulation. For details, see the main text. ABL1, tyrosine-protein kinase ABL1; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AT, acetyltransferase; AUTEN, autophagy enhancer; BCL-2, apoptosis regulator BCL-2; CMA, chaperone-mediated autophagy; DUB, deubiquitinase; GC, glucosylceramide; HSF1, heat shock factor 1; HSP, heat shock protein; LAMP2A, lysosome-associated membrane glycoprotein 2A; NDAs, neurodegenerative disorders of ageing; p38 MAPK, p38 mitogen-activated protein kinase; PKA, protein kinase A; PKG, protein kinase G; PtdIns3P, phosphatidylinositol-3-phosphate; RAGE, receptor for advanced glycation end-products; RARα, retinoid acid receptor-α; TAT, HIV transactivator of transcription; TFEB, transcription factor EB; USP14, ubiquitin carboxyl-terminal hydrolase 14; ZKSCAN3, zinc-finger protein with KRAB and SCAN domains 3. *Acts upstream (adenosine A 2A receptor agonist). 133 . In addition, rapamycin abrogated pathology in murine models of AD and FTD, in addition to countering neuronal loss in 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP)-treated mice [134] [135] [136] . Likewise, temsirolimus reduced the accumulation of phosphorylated tau in SH-SY5Y cells and P301S tauopathy mice 137 . It also removed cellular aggregates of mutant Htt and improved motor performance in a mouse model of HD, reduced α-synuclein aggregation and afforded neuroprotection in a lesion-based model of PD and depleted mutant ataxin 3 in a mouse model of supraspinal cerebellar ataxia type 3 (REFS 133, 138, 139 ).
Interestingly, several 'small-molecule enhancers of rapamycin' promoted autophagy and eliminated Htt in cellular and D. melanogaster models, but the precise role of mTORC1 in their actions remains to be clarified 140 . ). R275W is a mitophagy-linked parkin (PRKN) mutant mouse. GBA (which encodes β-glucocerebrosidase (βGCase)) mice include lines with natural (N370S and L444P) and induced (D409V) mutations. Lesion-based models of PD employ the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), okadaic acid or H 2 O 2 . ABL1, tyrosine-protein kinase ABL1; AC, adenyl cyclase; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK, 5ʹ-AMP-activated protein kinase; ATG, autophagy-related protein; AUTEN, autophagy enhancer; CaMKK2, calcium/calmodulin-dependent protein kinase kinase 2; ER, endoplasmic reticulum; HSF1, heat shock factor 1; HSP, heat shock protein; LC3, light chain 3; LPS, lipopolysaccharide; MCI, mild cognitive impairment; MTMR14, myotubularin-related protein 14; mTORC, mammalian target of rapamycin complex; NA, no data; p300, histone acetyltransferase p300; p38 MAPK, p38 mitogen-activated protein kinase; p62, ubiquitin-binding protein p62; PtdIns3P, phosphatidylinositol-3-phosphate; SIRT1, NAD-dependent protein deacetylase sirtuin 1; TFEB, transcription factor EB; TH, tyrosine hydroxylase; UPS, ubiquitin-proteasome system; USP14, ubiquitin carboxyl-terminal hydrolase 14; ZKSCAN3, zinc-finger protein with KRAB and SCAN domains 3. Apolipoprotein E allele 4 (APOE4). A robust genetic risk factor for Alzheimer disease compared with the more common APOE2 and APOE3 alleles. APOE is mainly secreted by astrocytes and binds lipids such as cholesterol, which are carried to neurons. APOE4 is also involved in transport of cholesterol-bound amyloid-β (Aβ) to the bloodbrain barrier (APOE4 is less efficient than APOE2 or APOE3) and in driving synthesis of Aβ fragment 42 (Aβ42) (APOE4 is more potent than APOE2 or APOE3).
Presenilin 1 (PS1).
A gene encoding the catalytic unit of the γ-secretase complex, which processes amyloid precursor protein (APP) into amyloid-β (Aβ). Mutations are associated with familial Alzheimer disease and in part reflect altered APP processing. In addition, reduced lysosomal acidification and autophagic-lysosomal network function may be involved owing to mutant presenilin 1-driven deficits in maturation and translocation of vacuolar-type H + -ATPase complex (v-ATPase) subunits to the lysosome.
Parkin
A component of the E3 ubiquitin ligase complex that binds to its partner PTEN-induced putative kinase protein 1 (PINK1) to facilitate the autophagic removal of dysfunctional mitochondria that have lost their membrane potential.
Gaucher disease
A primary, autosomal recessive lysosomal storage disease caused by mutations in the GBA1 gene, which encodes β-glucocerebrosidase (βGCase). There is a fivefold higher risk of Parkinson disease (PD) in affected carriers. The activity of βGCase is impaired in a subpopulation of patients with non-familial PD, which includes many patients who have genetic mutations related to lysosomal disruption.
The natural product curcumin induced macroautophagy and protected rotenone-treated dopaminergic neurons 141 in addition to accelerating the elimination of mutant α-synuclein-A53T by repressing mTORC1 in a cellular model of early-onset PD, although it also exerts other actions such as inhibition of p300-mediated protein acetylation and of aggregation 142, 143 . Pro-autophagic effects of curcumin are reflected in improved function in cellular and animal models of PD and AD, as well as reduced levels of α-synuclein aggregates 144 or Aβ and tau oligomers 145, 146 .
Given that phosphorylation by mTORC1 blocks translocation of TFEB from lysosomes to nuclei, mTORC1 inhibitors should promote the coordinated synthesis of proteins driving the ALN 20, 22, 147 . Indeed, TFEB overexpression reduced amyloid plaques in a APP/PS1 mouse model 148 . Moreover, the flavonol fisetin stimulated autophagic degradation of phosphorylated tau in cortical neurons via mTORC1-dependent activation of TFEB and the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2) 149 . Fisetin also reduced Aβ accumulation in an APP/PS1 mouse model of AD 150 .
Box 3 | Novel modalities for enhancing neurotoxic protein clearance
Classical small-molecule agents (such as those that are compatible with Lipinski's rule of five for orally available drugs) may not be suitable for some targets such as protein-protein interfaces and lipids. They are also not ideal for discrete delivery to specific brain regions. Here, we overview a suite of novel modalities for eliminating neurotoxic proteins in neurodegenerative disorders of ageing (NDAs).
Protein-protein interactions such as beclin 1-Bcl-2 can be disrupted by using a peptide that binds to one protein partner. The peptide itself is linked to a short, basic, arginine-rich sequence (derived from the HIV transactivator of transcription (TAT) protein) to improve cell penetrance. A TAT-beclin 1 construct triggered autophagy and cleared polyglutamine expansion protein aggregates in vitro 174 while also promoting long-term memory in rats 336 . Aptamers are small oligonucleotides that recognize specific proteins. They offer another chemically distinctive strategy for modulating clearance. Using this technology, the deubiquitinase, ubiquitin carboxyl-terminal hydrolase 14 (USP14) (REFS 49, 217 ) could be inhibited to facilitate tau clearance 214 . Inhibiting USP37, another proteasome-linked deubiquitinase, may also facilitate proteasomal clearance of neurotoxic proteins 337 . Similarly, aptamers moderated the autophagiclysosomal network (ALN) burden by blocking the misfolding and oligomerization of tau 338 and α-synuclein , including an increase of miR-34a in Alzheimer disease (AD), which neutralizes mRNAs encoding NAD-dependent protein deacetylase sirtuin 1 (SIRT1) and triggering receptor expressed on myeloid cells 2 (TREM2) (REF.
165
). Conversely, miR-132, which likewise interacts with SIRT1, is downregulated in AD 165 . Another example is the loss of miR-124 in a lesion model of Parkinson disease (PD) 340 . Selective targeting of mi RNAs in NDAs is becoming possible using modified oligonucleotides such as antagomirs, locked nucleic acids and miRNA sponges 165 . In addition, stabilized antisense oligonucleotides are showing promise for not only silencing mi RNAs such as miR-34 but also knocking out or altering the aberrant splicing of specific neurotoxic and/or aggregating proteins such as tau, mutant huntingtin (Htt), C9ORF72 and superoxide dismutase 1 (SOD1) (REF.
341
).
Proteolysis-targeting chimaeras (PROTACs) enable selective proteasomal elimination of unwanted proteins 342 . They are composed of two motifs joined by a linker: one recognizes a specific protein such as tau 236 , whereas the other encodes an E3 ligase binding site 234 . This allows the target protein to be polyubiquitylated, captured and degraded by proteasomes (and the ALN): addition of TAT-like motifs can increase efficacy 234 . In the 3×Tg AD mouse model, PROTACs moderated levels of tau in the cortex and hippocampus, suggesting target engagement in key pathological regions 234 . Interestingly, PROTACs may also be useful for orienting proteins towards chaperone-mediated autophagy (CMA) because the E3 ligase binding site can be substituted by a KFERQ CMA recognition motif. This approach was used to clear α-synuclein in vitro 233 . Smaller PROTAC variants offer improved stability, higher potency and better structureactivity relationships 343 .
Restoring lysosomal acidification using poly(d,l-lactide-co-glycolide) acidic nanoparticles proved neuroprotective in preclinical models of PD 344 . Although they are poorly brain penetrant, nanoparticles with improved pharmacokinetic profiles are being developed. Encouragingly, intranasal delivery reduced 6-hydroxydopamine-induced neurotoxicity in rats 345 . Another dimension of nanotechnology is represented by engineered nanorods, which, when internalized by HeLa cells, accelerated the ALN and cleared Htt aggregates in synergy with trehalose via the mammalian target of rapamycin complex 1 (mTORC1)-extracellular signal-regulated kinase (ERK) signalling pathway: in vivo actions and safety remain to be established 346 . One strategy for locally enhancing intracellular clearance is virally produced gene delivery to the pathological site, which avoids autophagic induction in healthy areas 347 . A target protein might be expressed in restricted areas using neuronal cell-specific promoters, such as the dopamine transporter in dopaminergic neurons 348 . Invasiveness of delivery is a drawback, but peripheral administration employing exosomes together with the use of focused ultrasound to favour local blood-brain barrier passage may offer a solution 349 . The latter approach increased access of small interfering RNA to the striatum for knocking down mutant Htt 300 . Furthermore, localized clearance was achieved with striatal lentivirus transfer of proteasome activator 28 subunit-γ (PA28γ), which binds the 20S subunit to form an immunoproteasome, leading to improved motor performance in a mutant Htt mouse model 350 . Another example is provided by intranigral gene delivery of beclin 1 or transcription factor EB (TFEB), which stimulated the ALN and alleviated pathology in α-synuclein-overexpressing mice 351 . Finally, recurrent exposure of mice to a non-invasive, 40 Hz flicker regime, which entrained GABA interneuron-driven oscillations in visual cortex, reduced the amyloid-β fragment 40 (Aβ40) and Aβ42 load; this resulted from a suppression of amyloidogenesis and a shift in microglial activation status, leading to enhanced uptake and clearance 352 .
Superoxide dismutase 1 (SOD1). A mitochondrial enzyme dedicated to the reduction of free radicals (reactive oxygen species). SOD1 mutations and dysfunction are seen in a subset of patients with amyotrophic lateral sclerosis.
CAG-expansion repeats
Proteins can contain multiple CAG repeats (CAG encodes glutamine (symbol Q)). When the number of CAG repeats is above normal (for example, greater than 35 for the huntingtin (Htt) protein), proteins aggregate, provoke cellular damage and trigger inherited, polyglutamine diseases such as Huntington disease, spinocerebellar ataxia 3/Joseph-Machado disease (involving the ataxin 3 protein) and spinal and bulbar muscular atrophy (involving the androgen receptor).
TAT-beclin 1
A synthetic peptide comprising 11 amino acids of the HIV transactivator of transcription (TAT) protein transduction domain, a diglycine linker and a (commonly 11-mer) sequence derived from amino acids 267-284 of beclin 1. It is cell penetrant and triggers autophagic-lysosomal network-mediated neurotoxic protein clearance without causing cytotoxicity, although higher concentrations may carry the risk of autosis.
Thus, mTORC1 -and possibly AMPK via poorly characterized cascades 21 -represents an option for stimulating TFEB. It remains, nonetheless, a challenging target for induction 22, 151 . Tyrosine-protein kinase ABL1 is a proto-oncogene that negatively regulates autophagy, partly acting upstream of the RAC serine/threonine-protein kinase (AKT)-mTORC1 axis. ABL1 is overactivated in AD and tauopathies such as FTD 152 . Inactivation of ABL1 with brain-penetrant nilotinib conferred neuroprotective autophagy in mouse models of PD 153 . It also reduced aggregates in cell and mouse models expressing TDP43 protein 154 . Nilotinib recently underwent a phase I safety study for treatment of PD 155 .
Modulators of SIRT1 and inhibitors of acetyl transferases. Activity of the deacetylase SIRT1 declines with age, partially owing to limited availability of its co factor, nicotinamide 24, 56, 156 . Therefore, it is interesting that nicotinamide and its analogues promoted autophagic removal of damaged mitochondria in fibroblasts 157 and reduced Aβ toxicity in rat cortical neurons 158 . They also improved mitochondrial energy generation and, partly as a consequence, reduced plaques in Aβ-expressing neuronal cells and AD mice while improving cognitive function 58 . Nicotinamide analogues similarly slowed cognitive decline and neuropathology in a 3×Tg AD mouse model 159 .
Resveratrol can stimulate SIRT1 via AMPK (see above), and it also possesses an AMPK-independent mode of SIRT1 recruitment that participates in blunting the neurotoxicity of Aβ25-35 fragments in PC12 cells 160 . This possibly involves a role for the DNA-repair protein, poly(ADP-ribose) polymerase 1 (PARP1). Its pharmacological inhibition elevates levels of the substrate, nicotinamide, with an enhancement of mitochondrial energy generation contributing to neuroprotective properties in an animal model of AD 160, 161 . Cilostazol (a phosphodiesterase 3 inhibitor) clears Aβ42 from neuronal cell lines by promoting autophagy, upregulating beclin 1, ATG5 and LC3, downregulating mTORC1 and inducing lysosomal cathepsin B; these actions of cilostazol involve activation of SIRT1 as well as upstream Tyr172 phosphorylation of AMPK 108, 162, 163 . Cilostazol improved cognition and reduced levels of Aβ42 and hyperphosphorylated tau following intracerebroventricular injection of Aβ25-35 into mice 162, 163 . Protein deacetylation, as effected by inducers of SIRT1, is of broader relevance to the ALN, as reflected by activation of ATG transcription 20, 24, 164 . Furthermore, acetyltransferases such as histone acetyltransferase p300 are druggable 20, 165 , and their inhibition (by garcinol) protected against autophagic deficits in a rodent model of PD 166 . Another p300 inhibitor, spermidine, has attracted attention by virtue of its autophagyrelated increase in longevity 164, 167 . Spermidine inhibits the acetylation of ATG7 and histone H3, while inducing beclin 1 via blockade of its cleavage by caspase 3 (REF.
168
). Spermidine also decreased disease progression in a mouse model of FTD 169 and reduced α-synuclein toxicity in Caenorhabditis elegans 170 . Depletion of acetyl CoA would be worth exploring in models of NDAs 171 . Underpinning interest in inhibitors of acetyltransferases, p300 expression is increased in AD brain and involved in the aberrant acetylation of tau 165, 167, 172, 173 . Inducers of autophagosome formation. As outlined in BOX 3, the cell-permeable peptide TAT-beclin 1 acts at the beclin 1-Vsp34 complex to increase autophagy and promote the clearance of Htt aggregates in cell lines 174 . In addition, the plant-derived alkaloid isorhynchophylline upregulated beclin 1 independently of mTORC1 and promoted autophagic clearance of α-synuclein, although its precise mechanism of action remains to be clarified 175 . Beclin 1 bears a BH3 element on its amino terminus that is subject to inhibition by the anti-apoptotic protein Bcl-2 (REFS 19, 165, 176 ). Disruption of this Bcl-2-beclin 1 complex is an alternative approach for promoting autophagy, as achieved in mouse fibroblasts by the BH3 mimetic ABT-737 (REF.
177
). A knock-in, gain-of-function beclin 1 mutant with reduced repression by Bcl-2 also increased autophagy, promoted Aβ sequestration and improved cognition in a 5×FAD mouse model of AD; this pattern was reproduced with ML246, a novel autophagy potentiator with an uncertain mode of action 178 . Other potential approaches to beclin 1 activation include inhibitors of (tau-phosphorylating) cyclin-dependent kinase 5 (REF.
179
The multi-modal agent resveratrol induced the expression of ATG4 and promoted autophagosome formation. This led to accelerated degradation of polyglutamine-Htt aggregates and protected SH-SY5Y cells from toxicity 180 . An unusual approach to augmenting autophagosome formation is represented by the brainpenetrant autophagy enhancer 99 (AUTEN-99), which blocks myotubularin-related protein 14 (MTMR14, also known as Jumpy), a phosphatase that inhibits the phosphoinositide 3-kinase (PI3K)-mediated generation of the autophagosome membrane (FIG. 3) . AUTEN-99 augmented autophagic flux in isolated neurons, increased markers of autophagy in mouse brain and slowed neurodegeneration in D. melanogaster models of PD and HD 181 .
Promoters of autophagosome transport and lysosomal fusion. Disruption of cytoskeletal networks and loss of microtubule function in NDAs compromise the transport of autophagosomes, late endosomes, amphisomes and retromers to perikaryal lysosomes. This impedes degradation of neurotoxic proteins [34] [35] [36] . Accumulation of autophagosomes and lysosomes in axonal swellings is associated with local APP processing into Aβ42, as well as plaque formation 16, 34 . The microtubule stabilizers paclitaxel and epothilone A countered Aβ42-induced cytoskeletal disruption -and moderated excessive UPR -in neurons 182 . Furthermore, epothilone D countered microtubule disruption and cognitive deficits in aged P301S/P19 AD mice 183 . However, it is unclear to what extent these agents promote ALN in the perikaryon, and a risk of cytoskeletal over-rigidity should not be neglected. Thus, mechanisms that promote microtubule and actin dynamics as well as cytoskeletal shuttling of autophagosomes and endosomes to lysosomes present alternative strategies for evaluation 184 .
Several other, potentially targetable mechanisms might also aid autophagosome delivery to (and fusion with) lysosomes 185 . These include RAB and RABeffector proteins, which facilitate the assembly of synataxin 17-SNARE complexes that are critical for fusion 186 . Interestingly, genetic or pharmacological activation of RAB5 countered neurodegeneration in mouse C9ORF72 models of ALS and FTD 187 . There is also growing interest in the stabilization of retromers for promoting fusion. This appears feasible by modulating their role in diverting APP out of endosomes and hence curtailing its cleavage into Aβ42 (REFS 37, 188 ). Finally, inducers of histone deacetylase 6, which is broadly implicated in cytosolic transport and the fusion of autophagosomes, might be an option 3 .
Facilitators of lysosomal digestion. Maintaining optimal intraluminal acidity is critical for activating lysosomal hydrolases and digesting cargo. There are several ways that a loss of lysosomal acidity in NDAs might be countered. First, lysosomal acidification could be favoured by stabilized cAMP analogues; in human fibroblasts bearing a presenilin 1 mutation, cAMP acidified lysosomes and augmented the availability of cathepsins 189 . Second, the TFEB inducer 2-hydroxypropyl-β-cyclodextrin promoted the acidity of lysosomes in neurons 190 . Third, acidic nanoparticles such as polylactic acid and poly(lactide-co-glycolide) increase acidification
. Fourth, activation of the lysosomal Ca 2+ channel mucolipin transient receptor potential channel 1 (TRPML1) with a synthetic agonist (ML-SA1) increased lysosomal Ca 2+ release, lowered pH and promoted Aβ clearance 191, 192 . Other approaches include the enhancement of v-ATPase activity and countering deficiencies in progranulin activity 40, 63, 86, [193] [194] [195] . Dysfunction of ATP13A2 leads to an imbalance in the handling of zinc, a disruption of lysosomal activity and accumulation of α-synuclein 77 . Clioquinol, which acts as a metal chelator, reverses these deficits and may reinforce lysosomal function (and acidification) in NDAs in which the regulation of zinc and other metals is abnormal 77, 196 . Indeed, clioquinol countered disruption of autophagy by chloroquine in retinal cells, reduced Aβ42 accumulation in CHO cells expressing APP and mutant presenilin 1 and diminished amyloid misfolding and aggregation in Tg2576 AD mice 196, 197 . Cystatin B and cystatin C are endogenous antagonists of the cysteine active site on lysosomal cathepsins, and their genetic downregulation ameliorated deficits in lysosomal proteolysis, synaptic plasticity and amyloid clearance in TgCNRD8 AD mice 198 . Pharmacological blockers of cystatins are currently being sought. In addition, upregulation of the retromer complex might stimulate provision of hydrolases to lysosomes 37, 188 . Lysosomal enzyme replacement is an established treatment for several primary LSDs, for example, βGCase supplementation for type I (non-neuropathic) Gaucher disease 43 ( Supplementary Box 1) . Owing to BBB impermeability, enzyme supplementation does not appear promising in PD. However, inhibition of substrate (glucosylceramide) synthesis by brain-penetrant GZ/667161 and GZ/SAR402671 reversed synucleinopathy in A53T-SNCA mice 199 . Another glycosphingolipid synthesis blocker, miglustat 43 , showed activity in cellular and in vivo models of PD 75 . One might also act upstream to promote lysosomal function by accelerating the import of functional enzymes. βGCase again provides a good example. Ambroxol acts as a molecular chaperone to promote folding of βGCase and aid its transit from the ER to lysosomes 43 . It increased expression of βGCase, normalized autophagy and accelerated degradation of α-synuclein in a stem cell model of dopaminergic neurons derived from patients with PD bearing mutations in βGCase 200 . Ambroxol, which also decreased ER stress in D. melanogaster 201 , reduced α-synuclein levels in overexpressing, transgenic mice 202 . It is being evaluated for use in idiopathic PD (Supplementary Table 4) . A downside of ambroxol is that it occludes the catalytic site of βGCase, but novel agents like NCGC607 avoid this untoward effect 203 . Intriguingly, while enhancement of βGCase conferred therapeutic benefit in animal models of PD, its inhibition by conduritol-β-epoxide was beneficial in a mouse model of ALS, underpinning the apparently distinctive nature of ALS in regard to ALN function and energy balance 90 ( Supplementary Box 3) . Finally, a more global approach for harnessing lysosomal activity would be the induction of TFEB 20, 22 . Harnessing TFEB by 2-hydroxypropyl-β-cyclodextrin promoted clearance of proteolipid aggregates and α-synuclein in a cellular model of PD 195, 204 . It also augmented the elimination of Aβ in a Tg19959/CRND8 mouse model of AD 173 . The protein kinase C (PKC) activator HEP14 stimulated nuclear translocation of TFEB to boost lysosomal gene transcription and reduced Aβ plaques in APP/PS1 AD mouse brains 151 . Modulation of DNA methylation and post-translational histone marking offer further opportunities for transcriptional control of lysosomal activity, while microRNAs (mi RNAs) could intervene at the level of translation 20, 165 
Clinical studies of agents that modulate the ALN. Some of the above-discussed agents have been clinically evaluated, alone or in association, in NDAs (Supplementary Table 1 ). For example, metformin has been evaluated for cognitive function and energetic status in AD; resveratrol has been evaluated for functional decline and Aβ load in AD; rilmenidine has been evaluated for motor performance in HD; and ambroxol has been evaluated for βGCase activity and motor function in PD. To date, despite some positive observations, unequivocal proof for symptomatic improvement and/or course-altering effects have not been provided for any drug (Supplementary Table 1 ). Long-term effects remain under study, no medication that specifically and exclusively induces the ALN has yet been therapeutically approved, and proof of target engagement in clinical trials remains challenging. Hence, it is premature to draw conclusions in regard to therapeutic efficacy.
In fact, the antioxidant edaravone, which decreased autophagy in ischaemic brain and macrophages 205 , was recently authorized for use in a subset of patients with Heat shock factor 1 (HSF1). A protein that occurs as a monomer in the nucleus and cytoplasm and is repressed by heat shock proteins such as heat shock 70 kDa protein (HSP70). Following disruption of proteostasis, heat shock proteins dissociate from HSF1 in order to aid protein folding. HSF1 then trimerizes and acts as a transcription factor to increase production of HSP70 and other neuroprotective proteins.
ALS
206 (Supplementary Box 3) . This appears paradoxical but fits with the suggestion that high ALN flux is detrimental under conditions of severe cellular stress in ALS 90 . Whether decreased ALN flux is genuinely implicated in the clinical actions of edaravone remains to be confirmed 3, 206 (Supplementary Box 3) .
Caloric restriction and exercise mimetics for promoting ALN clearance. The anti-ageing and lifespan-extending benefits of 'caloric restriction mimetics' expressed across a range of multicellular organisms are related, at least in part, to the induction of AMPK and SIRT1, which leads to promotion of autophagy 21, 24, 164, 207 . These mimetics are generally safe yet encompass agents that reduce ATP availability by interfering with neuronal glucose uptake. This may pose problems because compromised neuronal energy is itself a risk factor for NDAs such as AD and PD 25, 164 . Nonetheless, efforts to find well-tolerated, autophagy-inducing mimetics are continuing 164 , and clinical trials should prove instructive 25, 164 . Furthermore, there is increasing interest in pharmacological exercise mimics that exert putative neuroprotective properties via the modulation of AMPK, mTORC1, beclin 1 and other regulators of the ALN 21, 207 .
Enhancing clearance by the UPS and CMA Opportunities for pharmacological manipulation of the UPS and CMA in NDAs are less well established than those for the ALN, but there are encouraging routes of progress 2, [45] [46] [47] 55, 56, 68 . Furthermore, the UPS inhibitors bortezomib, carfilzomib and ixazomib are approved for the treatment of multiple myeloma, indicating that clinical application of UPS modulators is possible 3 .
Facilitation of chaperones acting on client proteins. One approach for reinforcing the UPS focuses on agents that target chaperones involved in the handling and recognition of neurotoxic proteins 2, 68, 208 . Of particular interest is HSP70, which interacts with the E3 ubiquitin-protein ligase CHIP to aid ubiquitylation of proteins destined for proteasomal destruction 208 . HSP70 binds to heat shock factor 1 (HSF1), and under conditions of neurotoxic protein stress, their dissociation leads to mutual activation, with HSF1 driving transcriptional generation of HSP70 and other chaperones that facilitate proteostasis 208, 209 . HSP70 also exerts a more general role in the refolding and disassociation of aggregated proteins 2, 3 . One promising agent is the hydroxylamine derivative arimoclomol, which increases the activity of HSP70 by augmenting transcriptional activity of HSF1 (REF.
210
Arimoclomol rescued cultured motor neurons from oxidative stress and from the pro-apoptotic actions of staurosporine 211 . It also mediated the removal of mutant SOD1 aggregates and improved motor function in a mouse model of ALS 212 . Supporting interest in arimoclomol, it mimicked recombinant HSP70 in reversing lysosomal pathology in fibroblasts from patients with LSDs (Supplementary Box 3) . In an alternative approach, the rhodocyanine derivative YM-1 allosterically promoted the activity of HSP70 to enhance degradation of polyglutamine proteins; these findings suggest potential utility in HD 213 . Furthermore, HSP70 has been co-administered with inhibitors (IU1 and its more potent derivative, IU1-47) of the deubiquitylating enzyme USP14 to enhance proteasomal degradation of tau [214] [215] [216] . USP14 inhibitors act by preventing deubiquitylation rescue of tau and other UPS substrates such as TDP43 and ataxin 3. They may also effect allosteric changes in proteasomal subunits 217 . Interestingly, USP14 inhibitors promote the ubiquitylation of beclin 1 to recruit the ALN 216 . HSP90 counters the effects of HSP70 by forming a complex with it to impede substrate ubiquitylation; it likewise exerts a suppressive influence on HSF1 (REFS 210, 218 ). Among compounds that inhibit HSP90, geldanamycin promoted elimination of both hyperphosphorylated tau and oligomeric α-synuclein in cell lines 219, 220 . Moreover, geldanamycin reduced Lewy-like bodies 221 and Htt aggregates in D. melanogaster neurites 222 and reduced tau in AD mice 219 . The less cytotoxic analogue of geldanamycin, 17-AAG, has improved brain penetrance. It decreased Aβ levels 223 , improved memory 224 and lowered tau in transgenic AD mice 224 . 17-AAG also reduced α-synuclein oligomers in H4 cells 220 . Another HSP90 inhibitor, HSP990, has shown promise in lowering Htt aggregates and improving motor performance in two mouse models of HD 225 .
Modulation of the phosphorylation status of the proteasome. Numerous classes of kinase phosphorylate the proteasome 68, 226, 227 . Phosphodiesterase inhibitors protect cAMP from degradation to recruit PKA and boost UPS activity. Accordingly, rolipram protected rat cortical neurons from Aβ-induced synaptic disruption 228 . Furthermore, in a transgenic tau mouse model of FTD in which 26S proteasomal activity was impaired, rolipram attenuated markers of tauopathy, improved memory and protected synaptic integrity by strengthening PKA-mediated phosphorylation of the RPN6 (also known as PSMD11) component of the 26S proteasomal subunit 229, 230 . RPN6 activation may also be involved in the anti-ageing effects of caloric restriction 56, 164 . Interestingly, resveratrol inhibits phosphodiesterase 4, suggesting that proteasomal recruitment is yet another component of its global impact on neurotoxic protein clearance 113 . One concern with phosphodiesterase inhibitors and/or PKA inducers is their wide range of targets (including AMPK), but it may be possible to target proteasome-specific isoforms. Furthermore, acting upstream of cAMP is an alternative strategy. Chronic administration of CGS-21680, a selective agonist of the AC-coupled adenosine A 2A receptor, restored proteasomal activity in cellular and murine models for HD via PKA-mediated Ser120 phosphorylation of the RPT6 component of the 19S subunit 231 . Another kinase that activates the proteasome (RPT6 subunit) -and directs it to dendritic spines -is CAMKK2 (REF.
227
). Its recruitment may account for proteasomal activation by the GABA A receptor antagonist bicuculline 52, 232 . Protein kinase G (PKG) similarly activates the proteasome, and inhibition of cGMP breakdown by sildenafil reduced neurotoxic protein aggregation in cardiomyocytes, encouraging further studies in NDAs 68, 226, 227 . p38 mitogen-activated protein kinase (MAPK) indirectly influences the phosphorylation status of the proteasome, probably via cAMP signalling 3, 68, 226, 227 . p38 MAPK depletion, or its blockade by PD169316, accelerated the degradation of ubiquitylated proteins, promoted α-synuclein clearance and improved cell survival 233 .
Phosphorylation is a dynamic process, and small-molecule inhibitors of the nuclear proteasome phosphatase ubiquitin-like domain-containing CTD phosphatase 1 (UBLCP1) suggest that calcineurin and other phosphatases represent hitherto-unexploited targets for improving UPS-driven clearance of neurotoxic proteins 227 .
Selective elimination of specific classes of neurotoxic protein. An important question is whether the UPS can specifically clear neurotoxic proteins while safeguarding those that function normally. Several strategies are under exploration. The first is targeted protein degradation with small molecules, which can be achieved by various compounds -including proteolysis-targeting chimaeras (PROTACs) and phthalimides that bind to E3 ubiquitin ligases and the protein of interest, thereby promoting UPS-driven degradation 234, 235, 236 
.
Certain agents amplify PROTAC-mediated breakdown of α-synuclein 233 , while other classes of bifunctional ligand bind a target protein plus HSP70 to direct UPS degradation 235 . Alternatively, target proteins can be bound by agents bearing bulky, hydrophobic adamantyl tags that provoke conformational instability and encourage proteasomal elimination 234 . Second, the cytosolic antibody receptor tripartite motif-containing protein 21 (TRIM21) binds to protein-coupled anti bodies then recruits the UPS for substrate degradation. This has been demonstrated for tau and could be adapted for degradation of other classes of neurotoxic protein 237 . Third, cellular inhibitor of apoptosis 1 (CIAP1; also known as BIRC2) specifically binds mutant SOD1 and drives it to proteasomal degradation. This provides another potential path to discrete elimination of unwanted proteins in NDAs 238 .
Control of transcription factors generating UPS components.
The transcription factors NFE2L1 and NFE2L2 (also known as NRF1 and NRF2, respectively) are both substrates of proteasomal degradation and inducers of proteasomal synthesis, and the latter activity has been specifically linked to NDAs 239, 240 . Furthermore, NFE2L2 is a master regulator of the antioxidant response and drives synthesis of lysosomal and anti-inflammatory proteins in addition to 26S proteasome components 149 . Translocation of NFE2L2 to the nucleus is promoted by triterpenoid derivatives that counter the ageing-related diminution of UPS activity 241 . In addition, sulforaphane elevates proteasome levels in vivo by inducing NFE2L2, protects neurons against oxidative stress and has been proposed for the treatment of HD 242 . Several other agents promote the proteolytic competence of proteasomes and facilitate clearance of Aβ and/or tau in cellular models, including betulinic acid. Increased transcription has been implicated in their actions, but this remains to be clarified 242 . Finally, mirroring its inhibitory influence on the ALN, mTORC1 suppresses the UPS by impeding the formation and assembly of proteasomal subunits. Correspondingly, pharmacological blockade of mTORC1 may promote UPS degradation as well as ALN elimination of neurotoxic proteins 243 .
Enhancement of CMA-mediated clearance. Some mechanisms outlined above for the UPS, such as increasing chaperone-driven delivery of client proteins to degradative machinery, are also relevant to CMA 47, 48, 95 . In fact, specific induction of CMA has received little attention, possibly because the rate-limiting element LAMP2A has, to date, proved intractable for small-molecule chemistry. Nonetheless, overexpression of LAMP2A accelerated CMA-related clearance of α-synuclein and afforded protection of dopaminergic neurons 45 , and several routes to potential pharmacological exploitation exist. First, cathepsin A cleaves LAMP2A, resulting in its lyso somal degradation, so selective inhibitors of cathepsin A should reinforce CMA 39, 47, 48 . Second, LAMP2A is stored in cholesterol-rich membrane regions; hence, cholesterol depletion might enhance transfer to regions where it is functionally active 46 . Third, the dynamics of the LAMP2A client protein translocation complex are (oppositely) controlled by mTORC2 and the phosphatase PH domain leucine-rich repeat-containing protein phosphatase 1 (PHLPP1), offering potential targets for augmenting CMA 244 . Fourth, CMA is under the negative control of retinoic acid receptor RXRα, and blockade by synthetic, all-trans retinoic acid derivatives resulted in upregulation of CMA, including the activity of LAMP2A 245 . Mouse fibroblasts treated with these agents showed improved resistance to combined overexpression of α-synuclein and oxidative stress 245 .
Importance of early intervention. There are, then, emerging opportunities for intensifying the elimination of neurotoxic proteins by the UPS and CMA 47, 68, 227 . However, it is important that they are homeostatically regulated because -mirroring the ALN -excess activity is potentially dangerous 241 . The UPS and CMA are disrupted by neurotoxic proteins like Aβ42 and tau, hence, their early and preventive reinforcement prior to Aβ42 and tau accumulation may be critical. UPS potentiation might be particularly efficacious when enacted in dendritic sites of neurotoxic protein spreading to counteract NDA-related deficits in synaptic plasticity and learning 1, 3, 5, 8, 47, 52, 68, 227 .
Interplay between the ALN, CMA and the UPS: therapeutic relevance. As pointed out above, there is evidence of coordinated regulation of the ALN and UPS via mTORC1 (REFS 1, 3, 5, 243 ). Furthermore, studies of a mutant tau allele that increases the risk of FTD and AD showed that upregulating the ALN compensated for the impairment of proteasomal activity 246 . This finding underscores the reciprocal interplay between these clearance systems 3 . Indeed, the ALN can sense UPS failure and compensates by upregulating its own activity. For example, proteasomal failure exacerbates ER stress and leads to the expression of sestrin 2 via the UPR, which recruits AMPK to downregulate mTORC1 upstream of the ALN; NFE2L2 is also upregulated 3 . Supporting the relevance of sestrin 2, it has been shown to protect dopaminergic neurons from the neurotoxin rotenone via AMPK-transduced autophagy 247 . Sestrin 2 over expression also prompted mTORC1-dependent autophagy in cortical neurons in a presenilin-knockout model of AD 248 . Proteasomal degradation of ULK1, LC3 and other ALN regulatory proteins may prevent ALN overactivity, an observation of particular relevance to ALS 3 (Supplementary Box 3) . By analogy, subunits of the catalytic core of the proteasome are regulated by CMA-mediated degradation 47, 55 .
Impaired extracellular protein clearance
Exosomal liberation of neurotoxic proteins from neurons. When intracellular pathways of protection against neurotoxic proteins prove insufficient, neurons may alleviate the burden of harmful proteins by discharging them into the extracellular space. This may be a self-preservation mechanism and an attempt to acquire glial support for elimination. However, the release of neurotoxic proteins contributes to trans-cerebral spread of pathology. That is, abnormal conformers of proteins originating in donor cells enter recipient cells to promote protein misfolding and disrupt clearance, diffusing in a domino-like or snowball-like fashion across the brain 81, 249 . Exosomes are involved in the release of tau, APP, possibly Aβ42 and α-synuclein. Accordingly, they are linked to the progression of NDAs 55, 77, 81, 250, 251 . Intriguingly, when the ALN is overwhelmed and cargo accumulates, a process of autophagic exocytosis participates in the neuronal liberation of neurotoxic proteins. This discharge of neurotoxic proteins adds to the extracellular burden from dying cells, accelerates spreading and underpins the importance of clearance mechanisms extrinsic to neurons 250, 252 . In this light, capture and digestion of extracellular proteins by glial cells are primordial 7, 8 . However, there exist several other, therapeutically pertinent mechanisms for ridding the brain of extracellular pools of neurotoxic proteins.
Clearance of neurotoxic proteins by proteases in the extracellular space. Neurons and glia contain diverse classes of protease, and they are localized in all the compartments where neurotoxic proteins accumulate -cytosol, mitochondria and even the nucleus 39, [253] [254] [255] [256] . However, certain intracellular proteases in the cytosol generate toxic fragments, notably of tau (calpains and caspases) and Htt (matrix metalloproteinases (MMPs)) 39, 257 . Accordingly, their inhibition rather than induction is of interest for the treatment of disorders such as AD and HD. Indeed, the inducible (extracellular) proteases most relevant to promoting neurotoxic protein clearance in NDAs are actively secreted by neurons and glia and are located on exosomes and/or expressed on plasma membranes 254 (FIG. 1) . They include several classes of MMP, neprilysin, insulin-degrading enzyme (IDE) and plasmin 253, 256, 258, 259 . Aβ42 and amylin (a pancreas-derived, AD-associated protein found in brain) are substrates for degradation by IDE, which also irreversibly traps Aβ42 and α-synuclein, preventing their aggregation and promoting ALN and UPS elimination 259 . Cerebral levels of IDE are reduced in early AD and in mouse models of AD, whereas, mirroring AD amyloidosis, Aβ42 accumulates in mice genetically depleted of IDE. In a vicious circle, Aβ42 itself decreases IDE expression, although it may prompt its release from glia 254, 259 . IDE also degrades and prevents the formation of α-synuclein fibrils 259 . Similar to IDE, neprilysin catabolizes Aβ42, and its loss in mouse models of AD and in patients with AD alike also contributes to Aβ42 accumulation 253, 256, 260 . Another Aβ42-degrading protease, plasmin, is derived from inactive plasminogen by the actions of tissue-type plasminogen activator (tPA), which is used to treat stroke. Plasmin is secreted by neurons (and possibly glia) into the extracellular space. Like IDE and neprilysin, plasmin degrades Aβ42 and blocks Aβ42-induced toxicity, suggesting that the decrease in its levels in AD is involved in the evolution of AD 254, 256, 261 . Plasmin also degrades α-synuclein to retard intercellular spreading 262 . Interestingly, certain isoforms of MMPs cleave fibrillar as well as monomeric Aβ42 (REF.
254
), while extra cellular α-synuclein is also a substrate for MMP3 (REFS 256, 258 ).
Another protease with pharmacotherapeutic potential is angiotensin-converting enzyme, which contributes, albeit less prominently, to degradation of neurotoxic proteins in NDAs 263 . Finally, the extracellular and intracellular serine protease neurosin (also known as KLK6) cleaves α-synuclein. Levels of neurosin are reduced in Lewy body dementia, and on the basis of lentivirus transduction studies, it is a potential treatment for clearing α-synuclein in PD 264 .
Clearance of neurotoxic proteins by the blood-brain barrier and the glymphatic system. In AD, HD and other NDAs, disruption of the structure and function of the dynamically regulated BBB is driven, at least in part, by detrimental actions of neurotoxic proteins such as Aβ42. This permits the otherwise restricted entry of immune cells and toxic substances into the brain. In addition, the active elimination of neurotoxic proteins like Aβ42 and tau (possibly encapsulated in exosomes) from the brain may be compromised [265] [266] [267] [268] [269] [270] [271] [272] [273] (FIG. 1; TABLE 1 ).
Dysregulation of BBB integrity is serious because it normally transfers neurotoxic proteins to the circulation using both generalized and specialized receptors and transporters [265] [266] [267] [270] [271] [272] (FIG. 1) . In addition, neurotoxic proteins are degraded by vascular smooth muscle and endothelial cells of the BBB itself 265, 271, 272 . In ageing, AD and PD, a diminution of BBB-localized P glycoprotein 1 (also known as ABCB1) efflux transporters compromises elimination of neurotoxic proteins 267, 273 . There are also decreases in levels of low-density lipoprotein receptor-related protein 1 (LRP1) transporters in AD, whereas advanced glycation end product-specific receptor (AGER, also known as RAGE) are induced. These changes would contribute to retention of Aβ42 in the brain and return of Aβ42 to the brain, respectively [270] [271] [272] . An APOE4 genotype in AD exacerbates poor Aβ42 clearance by reducing its transport to the BBB and diminishing efflux [270] [271] [272] . Arterial pulsing aids CSF and ISF flow in flushing out interstitial extraneuronal proteins via the complementary glymphatic system 265, 269, 274, 275 (FIG. 1) . Its regulation is not well understood, but roles for aquaporin 4 water channels, other astrocytic mechanisms and noradrenaline have been documented 265, 276, 277 . Deletion of aquaporin 4 in astrocytes markedly reduced glymphatic flow and aggravated Aβ42 accumulation in a genetic mouse model of AD 276, 278 , while aquaporin 4 expression is altered in the ageing, AD and PD brains 276, 277 . Loss of sleep has been linked to an impairment of glymphatic clearance and Aβ42 accumulation 274 . This is important because rapid eye movement sleep behaviour disorder is the most robust predictor of PD, while insomnia and anomalous sleep patterns occur in other NDAs like early-onset AD, where disrupted sleep is correlated with alterations in Aβ levels 279 .
Enhancing extracellular clearance Increasing protease-driven degradation. Overexpression of neprilysin or IDE reduces levels of Aβ42 and amyloid plaque burden in senescence-accelerated mice 256 . In regard to pharmacological manipulation, substances such as epigallocatechin and somatostatin promote the expression, secretion and (allosterically) catalytic activity of IDE and neprilysin in parallel with an increase in the degradation of Aβ peptides 259, 280 . Furthermore, expression of progranulin in the hippocampus of AD mice reduces the density of amyloid plaques by enhancing the activity of neprilysin 281 . Epigenetic regulation of neprilysin at the level of histones, as exemplified by valproate, offers another potential approach to proteolytic potentiation 253 . In regard to other proteases, augmentation of plasmin clearance by blockade of the plasminogen activator inhibitor 1 (PAI-1) (the expression of which increases with ageing and in murine models of AD) reduced Aβ levels and restored memory deficits in mouse models of AD 261, 282 . These observations underscore the interest in proteases as targets for degradation of neurotoxic proteins 253 . Furthermore, several agents mentioned above, such as resveratrol and curcumin, induce IDE and/or neprilysin, suggesting a contribution to their actions 253 . Nonetheless, structure-activity relationships for small molecules that enhance the catalytic activity (or production) of proteases are not well-characterized 253, 283 . Furthermore, there are issues of substrate specificity. For example, IDE degrades insulin and glucagon as well as Aβ42 and interacts with many other proteins, including the proteasome 259 . Neprilysin targets a range of substrates such as atrial natriuretic peptides and substance P, and inhibitors of neprilysin are used in the therapy of heart failure 253 , while MMP activators exert deleterious as well as beneficial effects, reflecting their influence on microglia and the BBB 258, 284 . Additional questions centre on whether any protease inducer alone could comprehensively and enduringly clear the burden of neurotoxic proteins in NDAs.
Thus, further work is needed to determine to what extent potentiation of extracellular, glial and endothelial/BBB-localized proteases is a viable strategy for safely enhancing neurotoxic protein clearance in NDAs 253, 259 .
Immunotherapies for neurotoxic protein sequestration.
Immunotherapies for neurotoxic protein clearance in NDAs have been pursued for over a decade. As reviewed elsewhere 81, 285 , the most advanced approach is currently antibodies for sequestering extracellular pools of Aβ and tau (AD) or α-synuclein (PD) 7, 286 . BBB antibody penetration is limited, but antibodies may generate a 'peripheral sink' in addition to exerting actions centrally. Although Aβ immunotherapy has not yet yielded an approvable treatment (examples of phase III trial failures include AN1792 (ClinicalTrials.gov registration number NCT00676143) and bapineuzumab (NCT00112073)), more refined cohort selection, amyloid imaging for selection of patients with early disease and the use of monoclonal anti bodies derived from human patients, such as aducanumab in mild cognitive impairment (in early-phase trials (NCT01397539, NCT02782975 and NCT02434718) and in currently recruiting phase III trials (NCT02484547 and NCT0247780)), offer hope for progress 287 . There are at least five immunotherapies under investigation for clearing tau. Active immunotherapy approaches are being used with AADvac-1, which is in a phase II trial in AD (NCT02579252), and ACI-35, a vaccine against a tau fragment phosphorylated at Ser396 and Ser404 (ISRCTN13033912) 81, 288 . Passive tau immunity approaches are being tested with the anti-tau antibodies RO7105705, which is in a phase II trial in AD (NCT03289143), and ABBV-8E12, which is in phase II trials in AD (NCT02880956) and in progressive supranuclear palsy (NCT02985879) 81, 288 . Targeting extracellular tau to block intercellular spreading 249 should preclude the need for high antibody inclusion in cells. Antibodies such as PRX002 (REF.
289
) have also shown promise for reducing extracellular α-synuclein and propagation of pathology, and phase I testing has been completed (NCT02157714 and NCT02095171) 285 . Potential problems should not be ignored, including the deposition of immune complexes in vascular tissue, inaccessibility of tau in exosomes and antibody-driven import of Aβ into the brain. Nonetheless, with the use of more effective antibodies and appropriate biomarkers, there are still reasonable prospects for achieving course alteration with immunotherapy.
Enhancing BBB-mediated and glymphatic transfer to the circulation. The BBB is equipped with potentially targetable transporter proteins, channels and receptors [265] [266] [267] [270] [271] [272] [273] ( FIG. 1) . Inhibition of the α-secretase disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) was found to drive LRP1-mediated extrusion of Aβ42 into the circulation 290 . In addition, LRP1 might be indirectly modulated by aquaporin 4 channels [276] [277] [278] and epigenetically via mi RNAs 165 . Furthermore, the hydroxymethylglutaryl-CoA inhibitor fluvastatin upregulated LRP1 in the BBB to provoke Aβ42 extrusion 291 . The antibiotic rifampicin likewise promoted Aβ42 clearance by inducing BBB-localized LRP1 and P glycoprotein 1 (REFS 273, 292 ).
Whether LRP1-driven uptake of Aβ42 by microglia (and hepatocytes) is involved in the favourable effects of LRP1 upregulation remains to be clarified 271 . Interestingly, both fluvastatin and rifampicin have additional mechanisms Immunotherapies Biological therapies that passively or actively boost the body's natural defences. Specific classes of antibody aim to neutralize neurotoxic proteins such as amyloid-β fragment 42 (Aβ42) or tau. Entrance to the brain is limited, but these antibodies may also act as a peripheral sink for neurotoxic proteins in the circulation. In the brain, antibodies probably act for the most part extrinsically to neurons.
-including a probable induction of the ALN -that contribute to beneficial actions in models of AD 291, 293 . As for RAGE inhibitors, they should temper re-entry of Aβ into the brain and exert anti-inflammatory properties 294, 295 . However, despite promising improvement in cognition in a phase II trial 296 , a phase III study with azeliragon (TTP488) in AD recently failed (NCT02080364 and NCT02916056) (see Related links). Interestingly, resveratrol downregulated RAGE as well as MMP9 -an effect that is related to decreased hippocampal load of Aβ42 (REF.
297
). Finally, at least in murine models of AD, agonists of retinoid-X receptors induce BBB-localized P glycoprotein 1, and this may account for bexarotene-mediated Aβ clearance from the brains of AD mice 298 . Data with bexarotene remain controversial, but the principle of acting via BBB-localized transporters to encourage neurotoxic protein extrusion is clearly valid.
Focused ultrasound therapy has mainly been used to enhance the entry of proteins and vectors into the brain. For example, it promoted the entry of small interfering RNA (siRNA) probes for knocking down Htt and it could, in principle, be used to increase brain entry of genes encoding clearance-promoting mechanisms 299, 300 . Furthermore, ultrasound acts bi-directionally, so central nervous system-to-periphery transfer of neurotoxic proteins might be accelerated. By targeting selective brain areas such as the hippocampus/entorhinal cortex in AD, neurotoxic proteins could be driven into the periphery. Safety is obviously an issue, but it is reassuring that gap junctions close 6 hours or less after termination of ultrasound exposure 301 . Activation of aquaporin 4 channels on perivascular astrocytes to aid the glymphatic elimination of cerebral Aβ and other toxic proteins is a potential strategy for stimulating clearance. Both antagonists and positive modulators have been identified, so this seems chemically feasible 269, 272, 275, 278 . A contrasting approach is represented by dobutamine, which stimulates arterial pulsation and the perivascular/glymphatic CSF flushing of neurotoxic proteins from the ISF via lymphatic conduits into the blood 269, 275 . Deposition of Aβ42 in cerebral vessels impairs vascular flexibility and is accompanied by an upregulation of phosphodiesterase 3 in smooth muscle cells 302 . Cilostazol, a phosphodiesterase 3 inhibitor clinically approved for peripheral vascular disease (and a UPS activator), restored vascular reactivity, increased perivascular drainage of Aβ and promoted cognitive performance in a mouse model of cerebral β-amyloidogenesis 302 . Intriguingly, a retrospective clinical analysis suggested that cilostazol (added onto donepezil) abrogates cognitive decline in patients with modest dementia 303 . Adrenergic mechanisms influence ISF volume and hence neurotoxic protein clearance 274 , and additional pharmacological opportunities for promoting glymphatic efflux will probably emerge from an improved understanding of its regulation by astrocytic, neurotransmitter-related and other mechanisms 269, 272, 274 . Disruption of sleep impedes glymphatic clearance of neurotoxic proteins, so encouraging sleep hygiene should promote CSF/ISF transfer to the periphery 274, 275 . The atypical antidepressant and sleep-promoting agent trazodone is of interest because it normalized an over-protracted UPR and accordingly reversed pathology in animal models of tauopathies 99 (Supplementary Box 2). Other therapies that favour sleep in NDAs may improve glymphatic clearance of proteotoxic substrates and hence abate disease progression 265, 269, 279 . Interestingly, alcohol displays a J-shaped curve, with low or high consumption respectively enhancing or reducing glymphatic function and moderating or aggravating the risk of dementia 304 . Finally, in a recent study in human subjects, peritoneal dialysis cleared peripheral Aβ from the circulation, while parallel experiments in APP/PS1 mice showed that peritoneal dialysis reduced ISF and brain Aβ load and ameliorated behavioural deficits 305 .
Therapeutic perspectives and open questions Accumulation of neurotoxic proteins unquestionably contributes to the onset and progression of NDAs. Accordingly, agents that promote their elimination are attractive as potential therapeutic agents. Nonetheless, several issues remain to be resolved before successful and safe clinical exploitation.
First, improved knowledge of the causes, characteristics and chronology of poor clearance in NDAs, and of similarities and differences between them, would be important for clarifying which therapeutic strategy is best adapted to the treatment of specific classes of NDA and subsets of patients. This would also help determine the optimal mode, timing, pattern and dosage of treatment 4 . Second, it is important to better understand the interplay between neurotoxic protein clearance and other pathophysiological processes, such as neuroinflammation. Moreover, hub proteins such as AMPK, mTORC1 and SIRT1 affect both the ALN and manifold other processes implicated in NDAs, such as epigenetic regulation and energy homeostasis 21, 24, 25, 306, 307 . Hence, drugs that modulate their activity may have beneficial and/or deleterious actions beyond their influence on clearance. Indeed, potential side effects should not be ignored. This is exemplified by mTORC1 antagonists such as rapamycin, which possess immune-suppressive actions and affect memory formation, although studies in oncology and neurodevelopmental disorders are reassuring 5, 307 . Third, numerous mechanisms remain to be pharmacologically harnessed. These include receptor tyrosine kinases for the ALN and upstream GPCRs for potentially all modes of elimination 26, 27, 29 . For the ALN, additional targets include the Vps34 complex, histone deacetylase 6 (REF.
3 ), RAB proteins implicated in autophagosome-lysosome fusion 186 and v-ATPase, which is crucial for lysosomal acidification 40 . There has been much recent progress towards manipulation of the UPS, whereas exploitation of CMA remains a major challenge 2, 3, [45] [46] [47] 68, 80 . For certain targets, novel platforms such as PROTACs, aptamers and RNA probes, as well as nanoparticles and nucleic acid-based therapeutics, may prove useful
. Novel technologies will also be of importance for achieving the specific clearance of neurotoxic versus normal proteins and for directing actions to discrete cells and brain regions, such as dopaminergic pathways in PD 8, 45 . Further research is needed to confirm, clarify and potentially exploit the role of glymphatic clearance in the elimination of neurotoxic proteins in NDAs 308 . Another line of research could focus on how the blood-CSF barrier, which has parallels and differences to the BBB, is affected in ageing. It also represents a potential site for acceleration of neurotoxic protein elimination; its contribution to clearance of Aβ42 is diminished in AD 269, 272, 309, 310 . Fourth, to improve the preclinical characterization of candidate medicines, we need more refined cellular and animal models, including induced pluripotent stem cells from patients 1, 3, 4, 10, 23 
. This will help to determine precisely which components of the ALN, CMA and the UPS are affected by specific classes of medication and to quantify their influence on overall ALN flux. Improved models should also help determine the influence of therapeutic agents on clearance in discrete classes of neuron in comparison with astrocytes and microglia, which may well require contrasting modes of manipulation. Improved models and measures should also facilitate the development of translational readouts for clinical trials. Studies of the multi-functional ALN promoter and aggregation inhibitor methylene blue exemplify the challenges faced in patient selection, trial design, doseresponse relationships, readouts of efficacy and optimal time of intervention (Supplementary Table 4) .
Fifth, improved clearance may well have a broad therapeutic time window, yet early treatment would be advantageous, especially in regard to reinforcement of the UPS and CMA before aggregation predominates. Hence, reliable biomarkers of clearance will be important for detecting pre-symptomatic subjects for early intervention 81, 311 . Biomarkers are likewise crucial for demonstration of target engagement and as surrogate signals of disease-slowing and long-term efficacy. Although technologies for real-time monitoring of the ALN, CMA or the UPS in human brain are not currently available, quantification of CSF and plasma levels of neurotoxic proteins like Aβ42 and tau is instructive.
Furthermore, imaging of neurotoxic protein load is helping enrolment of subjects into clinical trials 311 . In addition, retinal imaging offers a window into cerebral accumulation and clearance of Aβ42 and tau 312 , while biomarkers of neurovascular flow from the brain to the circulation are under development 265, 275 . Sixth, the therapeutic strategies evoked herein are pertinent to other classes of NDA. For example, MachadoJoseph disease (spinocerebellar ataxia type 3) is an autosomal dominant, polyglutamine disease provoked by over-repetition of a CAG sequence in the ataxin 3 gene. The mutant protein destabilizes beclin 1 (REF. 94 ).
Accordingly, studies in transgenic mice and fibroblasts from patients suggest that reinforcing beclin 1-dependent ALN flux would be beneficial 313, 314 . Blockade of mTORC1 to induce autophagy (and the UPS) may likewise be useful.
Finally, reinforcing clearance might best be undertaken in association with other strategies like suppression of protein misfolding, amelioration of cerebral energetics or moderation of neuroinflammation. Drug combinations or multi-target agents possessing complementary mechanisms of action are both viable options. In addition, therapies for promoting neurotoxic protein clearance will probably prove most effective when used in conjunction with lifestyle changes such as improved sleep hygiene, exercise and a healthy diet.
Concluding comments
An excessive neurotoxic protein load is a core pathophysiological feature underlying and driving NDAs. Among several potential strategies for alleviating this burden, an enhancement of neurotoxic protein clearance is particularly attractive in view of the range of options available and because insufficient elimination is itself implicated in the pathogenesis of NDAs. Although challenges remain, the various mechanisms of clearance that are discussed above offer potentially important strategies for preventing the onset and progression of diverse classes of NDA.
